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Summary 
  
3 
 
In all eukaryotes, pre-mRNA splicing is a necessary step for protein synthesis. Pre-mRNA splicing is 
mediated by the spliceosome, a dynamic complex of 100/150 proteins and RNAs, which is 
assembled de novo at every splicing event. The same pre-mRNA can be spliced in different ways 
generating different isoforms that potentially regulate gene expression or affect protein structure, 
function, or localisation. RNA binding proteins, finely regulate this process by recognising short 
sequences located in the exons or in the neighbour introns that favour the inclusion or the exclusion 
of an exon in the mature mRNA.  
The advent of RNA sequencing has allowed the investigation of the splicing patterns and 
concurrently the quantification of mRNA abundance underlying a phenotype. Currently, the 
interpretation of the changes in the splicing patterns and their regulation represents one of the 
major challenges in biomedical research. 
To collect in a unique resource all the regulatory elements and the RNA-binding proteins that were 
spread across different repositories, we developed a database named ATtRACT. Subsequently, we 
investigated the impact of alternative splicing in the pig infarcted myocardium.  The analysis focused 
on four different cell types, cardiomyocytes, fibroblasts, endothelial cells, and macrophages at three 
different time points before and after infarction. We employed two distinct pipelines that allowed 
us to detect isoform switches after myocardial infarction, and to identify, thanks to the data 
available in ATtRACT, the RNA binding proteins and associated motifs that potentially regulate the 
alternative splicing. 
The analysis of the biological impact of large gene/protein sets is currently an open issue in 
bioinformatics. A widely-adopted procedure involves the enrichment analysis. Here, we developed 
a new functional enrichment analysis method, called MAGNETO. The main aim of MAGNETO was to 
gain more insight into of the biological processes underlying a phenotype by employing protein-
protein interaction networks.  
Our results show that ATtRACT represents an invaluable resource for all the researchers involved in 
the study of RNA binding proteins. ATtRACT adds 192 motifs not available in any other database by 
retrieving the information buried in the Protein Data Bank. Two hundred and ten genes were 
detected as alternatively spliced after myocardial infarction in cardiomyocytes, fibroblast, 
endothelial cells, and macrophages. Forty-one were also detected at the protein level. Moreover, 
our findings suggest that alternatively spliced isoforms could be of great use to develop novel 
therapeutic approaches to avoid adverse cardiac remodelling and improve cardiac repair. Finally, 
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our results confirm that MAGNETO allows to gain more overrepresented terms with respect to the 
standard enrichment analysis and to generate new hypotheses on the phenotype under 
investigation. 
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Resumen 
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En eucariotas, el splicing de pre-ARN mensajero (pre-ARNm) es un paso indispensable en la 
producción de proteínas. Este proceso está mediado por el Spliceosoma, un complejo de unas 100-
150 proteínas y ARNs. Un mismo pre-ARNm puede ser procesado de manera diferente generando 
isoformas alternativas que pueden alterar el nivel de expresión del gen o la estructura de la proteína 
y por consiguiente su función y/o localización. Las proteínas de unión a ARN regulan de manera muy 
precisa este proceso mediante el reconocimiento de secuencias de nucleótidos específicas 
(motivos) presentes a lo largo de la molécula de ARN mensajero que a la postre definirán la 
presencia de exones e intrones y permitirán modular la inclusión o exclusión de los exones en el 
ARN maduro. 
La llegada de las nuevas tecnologías de secuenciación masiva (NGS) ha permitido un estudio más 
exhaustivo y cuantitativo de los patrones de splicing presentes en una condición fenotípica dada. 
Actualmente, la interpretación de los cambios en los patrones de splicing y la regulación de los 
mismos es uno de los mayores desafíos en la investigación biomédica. 
Para ayudar en el estudio del AS es necesario tener un acceso fácil y exhaustivo a la información 
disponible sobre las proteínas reguladoras y sus motivos. Actualmente esta información se 
encuentra repartida in distintas bases de datos con distintas estructuras y de difícil acceso. Por ello 
he desarrollado ATtRACT, una base de datos con acceso vía web, que recopila y estructura toda esa 
información en un solo repositorio. Además en ATtRACT he añadido 192 motivos más obtenidos de 
las estructuras cristalográficas almacenadas en el “Protein Data Bank” (PDB) que no están 
disponibles en ninguna otra base de datos. 
La interpretación del impacto biológico que un grupo de genes, que cambian en una condición dada, 
es a día de hoy un problema fundamental y sin resolver. Actualmente el método mas empleado para 
ayudar en esta interpretación en el análisis de enriquecimiento en términos ontológicos. Este 
análisis es muy simple y sufre de varías carencias como no englobarse en el contexto biológico y no 
ser eficiente cuando el número de genes es bajo. Por ello he desarrollado MAGNETO, un nuevo 
método de análisis de enriquecimiento que incorpora la información disponible sobre las 
interacciones proteína-proteína, las vías de señalización donde están implicadas y el tejido sobre el 
cual se han obtenido los datos. Nuestros resultados muestran que MAGNETO es capaz de obtener 
más términos sobrerrepresentados y más específicos que los métodos tradicionales, especialmente 
cuando el número de genes en la lista es bajo (~50 genes). MAGNETO permite profundizar de 
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manera más precisa y eficiente en los procesos biológicos afectados en una condición fenotípica 
dada. 
A continuación hemos estudiado el impacto del splicing alternativo en el infarto de miocardio en 
cerdo. El análisis se ha focalizado en cuatro tipos celulares, cardiomiocitos, fibroblastos, células 
endoteliales y macrófagos a tres tiempos (0, 3 y 7 días) después del infarto. He empleado dos 
métodos de detección de cambios en isoformas de ARNm, a partir de datos de RNA-seq, que han 
permitido identificar 210 genes que cambian las isoformas de ARNm que producen debido al infarto 
de miocardio y durante su recuperación en los cuatro tipos celulares. Gracias a ATtRACT hemos 
podido profundizar en los mecanismos que regulan esos cambios identificando las posibles 
proteínas reguladoras y sus motivos de unión. De esos 210 cambios, 41 han sido detectados también 
a nivel de proteína. También MAGNETO ha ayudado en la interpretación de los cambios biológicos 
que sufren los distintos tipos celulares durante el proceso de recuperación del infarto de miocardio 
mediante el análisis de las 50 proteínas más expresadas en cada tipo celular y a cada tiempo. 
Nuestros resultados sugieren que las isoformas alternativas podrían ser una nueva diana 
terapéutica para prevenir un remodelado cardíaco adverso y mejorar la reparación del miocardio. 
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Myocardial Infarction 
Cardiovascular diseases (CVDs) are the most common cause of death and hospitalisation worldwide. 
It is estimated that 15.6M people died of CVD in 2010, representing 29.6% of global deaths. Only in 
Europe, despite steady decreases, CVDs are responsible for 45% of all death equating to more than 
4 million deaths per year (Townsend et al. 2015). CVDs dramatically reduce life expectancy, quality 
of life, working years, and mobility. Among CVD, coronary heart diseases (CHDs) are the 
predominant contributors to CVDs. Myocardial infarction (MI) is the major clinical manifestations of 
CHD (Wong 2014). 
Myocardial infarction: definition and causes 
MI is the end result of a process, typically lasting for decades, called atherosclerosis. Atherosclerosis 
is characterized by the accumulation of cholesterol deposit in the coronary arteries. The disruption 
of an atherosclerotic plaque results in the release of a blood clot which leads to the blockade of the 
blood flow through a coronary artery (Woollard & Geissmann 2010). The interruption of the blood 
flow connected with the reduced functionalities of the heart is termed MI or commonly heart attack. 
Reperfusion of the blocked artery and restoration of the blood flow reduces the immediate 
mortality, but it still causes massive cell death due to oxidative damage. All these changes 
progressively lead to a decline in cardiac function and eventually to the heart failure. 
Structure of the normal myocardium 
Three are the main cardiac cell types in a healthy myocardium: Cardiomyocytes (CMs) Endothelial 
cells (ECs) and Fibroblasts (FBs). CMs are the core machinery and are responsible for the cardiac 
contraction-relaxation cycle. To perform their function, the CMs are aligned in parallel and in 
contact with each other. The fuel to perform these functions mainly comes from mitochondria 
which occupy one-third of the whole volume of the CMs (Schaper et al. 1985).  FBs are the most 
abundant cells in an healthy adult mouse ventricles (Pinto et al. 2016). The relative abundance of 
each resident cardiac cell is still uncertain and depends mainly on the species, age, and gender 
(Table 1). FBs are responsible for producing the extracellular matrix, and transmitting the 
mechanical signal to the CMs (Kakkar & Lee 2010). To work properly, CMs require oxygen and 
nutrients that are provided through the interacting ECs. Heart functions are regulated by the 
physical interaction and by the complex interplay between CMs, ECs, and FBs. 
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Table 1: Main cardiac cell types and their relative abundance. Adapted from (Talman & Ruskoaho 2016) 
Cell type Cardiomyocytes Endothelial 
cells 
Fibroblasts Macrophages and 
other leukocytes 
Pericytes and other 
mesenchymal cells 
Percentage 30% 45% 11% 6% 8% 
 
The three phases of MI 
The lack of oxygen-rich blood and nutrients due to ischemia leads to massive deaths of the cardiac 
resident cells. The reperfusion of the blocked artery, meaning the restoration of the blood flow, 
facilitates the CMs salvage and reduces immediate mortality, but it still causes massive cell death 
due to oxidative damage. To compensate this massive cell death, the myocardium starts a series of 
events that can be divided into three overlapping phases (Table 2): (i) an inflammatory phase, (ii) a 
proliferative phase, and (iii) a maturation phase. During these phases the reparative process takes 
place and the damaged ischemic tissue is progressively replaced by a fibrotic scar produced by FBs 
in order to prevent the cardiac rupture.  
The inflammatory phase 
The inflammatory phase lasts for 1-3 days. CMs are less resistant to the lack of oxygen with respect 
to FBs and ECs. For this reason, it has been proposed that CMs are responsible for triggering the 
inflammatory reaction in order to preserve the remaining cells and to replace the necrotic CMs. 
Since ECs, FBs and cardiac mast cells are more resistant to oxidative stress, it has been suggested 
that these cells are the responsible for receiving the signals from necrotic CMs and activating the 
innate immune system response (Shinde & Frangogiannis 2014; Frangogiannis 2014). The 
extracellular matrix (ECM) is degraded by FBs and allows the leukocyte and macrophages (MFs) 
infiltration into the ischemic tissue. The main role of macrophages and leukocytes is to clear dead 
cells and ECM debris and allowing the infiltration of new MFs and mononuclear cells and later of 
FBs for the deposition of the new ECM.  
The proliferative phase 
The proliferative phase starts approximately 3 days post-MI and can last for weeks. The trigger 
signals that activate the transition from the inflammatory phase to the proliferative phase are poorly 
understood.  During this phase, the cells recruited and infiltrated in the infarcted tissue during the 
inflammatory phase are subjected to apoptosis. FBs are then activated to secrete ECM proteins in 
order to: (i) increase the myocardium tensile strength, (ii) produce the fibrotic scar to prevent the 
cardiac rupture, (iii) favours the cell migration along the new ECM matrix (van den Borne et al. 2010; 
Shinde & Frangogiannis 2014). 
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Table 2: The different phases taking place after myocardial infarction. The inflammatory phase lasts for 1-3 days. During this phase the innate immune response is activated and the 
extracellular matrix is degraded allowing the leukocyte and macrophage (MF) infiltration into the ischemic tissue. The proliferative phase starts approximately 3 days post-MI and 
can last for weeks. During this phase the cells recruited and infiltrated in the infarcted tissue during the inflammatory phase are subjected to apoptosis. FBs are then activated to 
secrete ECM proteins. The ECs proliferate and infiltrate the infarcted area to promote the development of the microvascular network. Then the maturation phase takes over. It lasts 
for weeks, and the main role is to stabilize the infarcted area. Adapted from  (Talman & Ruskoaho 2016) 
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Additionally, the ECs start to proliferate and infiltrate the infarcted area to promote the 
development of the microvascular network and support FBs with oxygen and nutrients for 
proliferation and repair process (Deb & Ubil 2014). 
The maturation phase 
Afterwards, the maturation phase takes over. The main role of the maturation phase, which lasts 
for weeks, is to stabilize the infarcted area. During this phase, most of the FBs and ECs activate the 
apoptotic pathway, the remaining FBs produce type III collagen to progressively substitute the type 
I collagen in order to increase the stiffness of the scar (Dobaczewski et al. 2010). For a complete 
review (Talman & Ruskoaho 2016). 
Molecular regulation of cellular processes – RNA molecules  
In higher eukaryotes, RNA molecules are originated from DNA which is transcribed into a precursor 
RNA (pre-mRNA). To facilitate maturation of the mRNA, a big molecular complex called spliceosome 
is assembled. The main task of the spliceosome is to remove the introns in the pre-mRNA and to 
link the exons together. Splicing is not a rigid process and allows an alternative combination of 
exons, leading to the generation of different transcripts and proteins from a single gene. RNA 
binding proteins (RBPs) finely regulate these processes. RBPs define which exons are maintained or 
skipped, stabilise the mRNA, and export it from the nucleus to the ribosomes.  
RNA binding proteins 
RNA binding proteins (RBPs) are the key regulators of several cellular processes at mRNA level. 
Through their binding with RNA, RBPs regulate and control multiple processes including alternative 
splicing, transport, localization and stability (Glisovic et al. 2008). RBPs directly interact with RNA  
through particular domains, by recognizing short sequences (6-7 nucleotides long on average) called 
RNA binding motifs (Lunde et al. 2007). Typically, RBPs recognize thousands of binding sites and 
potentially regulate thousands of transcripts (Smith & Valcarcel 2000; Barash et al. 2010) with 
different specificities and affinities. Recent advances in the detection methods and in the solved 
crystallographic structure of ribonucleoprotein complexes started to shed light on the complex 
mechanism in which RPBs and RNA are involved in. However, we are currently far from a 
comprehensive characterization of the complex mechanisms regulating RNA and RBPs interaction 
and an in-silico prediction of RBPs targets and of post-transcriptional gene regulation remains a 
challenging task. Finally, alterations in RBPs are implicated in many human diseases such as 
neuropathies, muscular atrophies and cancer (Lukong et al. 2008).  
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RNA recognition by RNA-binding domains 
The RNA-binding domains (RBDs) present in the RBPs are the responsible for the recognition and 
binding to RNA. The most representative RBDs in eukaryotes are the RNA Recognition motif (RRM), 
the K Homology (KH) domain, the Pumilio homology domain (PUM) and the Zinc finger domain. 
RBDs can be found in a single or multiple copies along the RBPs. The majority of RBPs contain 
multiple copies of the same domain in order to selectively recognize larger and more complex 
transcripts. The usage of multiple RBDs allows increasing the specificity and the target recognition.  
RBPs containing only a single copy of RBD usually do not have the strength to interact with RNA in 
a sequence-specific manner. To increase their specificity, those RBPs containing only one RBD: (i) 
expand the size of the binding site or (ii) cooperate with other RBPs (Lunde et al. 2007; Jankowsky 
& Harris 2015a; Ascano et al. 2012).  
Single RBDs typically recognize short motifs ranging from 4 to 8 nucleotides. Moreover, the RBDs, 
usually, recognize degenerate motifs, thus the number of potential interactions and the number of 
potential binding sites is extremely large (Lunde et al. 2007; Jankowsky & Harris 2015b). The 
crystallography and NMR structure of RBP-RNA complex highlighted the role of hydrogen bonds and 
van der Walls forces in the RBP-RNA interaction. Hydrogen bonds, both from the protein backbone 
and the side chain, contribute to the RNA recognition, while the van der Walls forces enhanced the 
affinity between RBP and the nucleotides (Jones et al. 2001; Chen & Varani 2013). 
Experimental methods for the identification of RBPs 
RBP-RNA interactions can be detected through many methods, but essentially can be divided into: 
(i) low-throughput and (ii) high-throughput techniques. These techniques can be further divided in 
in-vivo and in-vitro depending on where the experiments are performed. Each of the methods has 
its own advantages and drawbacks. For example, in Systematic Evolution of Ligands by EXponential 
enrichment (SELEX), the binding affinity between RBP and RNA is determined by the alignment of 
sequences with a strong preference to bind to RBPs. The result is a consensus sequence that reflects 
the binding affinity between the RBP and the motif. SELEX has clear limitations because each 
position is not evaluated quantitatively and does not reveal the protein affinity for sub-optimal 
motifs. In RNAcompete as well as in SELEX there is the chance to identify a false positive target. CLIP-
seq experiments cross link the RBP to the RNA using UV radiation. UV cross-linking establishes 
covalent bonds between proteins and RNA. The main problem is that UV cross-linking binds 
preferentially certain nucleotides and certain amino acids (Ule et al. 2005). Experimental limitation 
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coupled with the complex interplay between RBP and RNA make the task of determining RBP 
binding sites a challenging problem. 
 
 
Basal splicing machinery 
Splicing is an eukaryotic regulatory mechanism by which the exons are ligated together and the 
introns are excised from the precursor-mRNA (pre-mRNA) (Fig 1). Splicing of the precursor-mRNA 
(pre-mRNAs) is catalysed by a ribonucleoprotein complex called spliceosome that is comprised of 
more than 100 proteins and five small nuclear RNAs (U1, U2, U4, U5, and U6) (Will & Luhrmann 
2011). Four well conserved exonic and intronic signals located within the intron are necessary for 
the spliceosome assembly (Fig 2): (i) the donor site (5’ at the beginning of the intron), the acceptor 
site (3’ end of the intron), the branch point and the polypyrimidine tract. The first step in the 
spliceosome assembly is the recognition of the consensus sequence GTRAGT (where R can be A or 
G) at 5’ splice site by the U1 snRNP. The branch site and the 3’ splice site are recognized by the U2 
snRNP.  The U4, U5 and U6 snRNPs are then recruited to act as a link between the U1 and U2. Then, 
a series of conformational rearrangements allows the bending and the breaking of the intron and 
exons are joined together (Wahl et al. 2009). 
Figure 1: In the canonical splicing the introns are removed and the exons are ligated together. 
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Alternative splicing and alternative splicing events 
Alternative splicing (AS) refers to the phenomena whereby the pre-mRNA may be spliced in a 
different combination in order to produce an alternative transcript and, potentially, a protein with 
a different structure, function or localization.  
AS produces different mRNA variants by skipping, shortening and extending exons, retaining introns 
or via different usages of alternative splice sites. The isoforms represent the possible different forms 
of mature mRNA that can arise from a single gene.  
Figure 2: Spliceosome assembly. The stepwise assembly of the spliceosome is shown. The non-snRNP proteins are not shown. 
Adapted from (Wahl et al. 2009). 
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Figure 3: The different AS events. Exon skipping (a), Alternative 3’ start site selection (b), Alternative 5’ start site selection (c), Intron 
retention (d), Mutually exclusive splicing (e), Alternative poly-(A) (g). Reproduced from (Keren et al. 2010). 
AS events can be classified in different ways: 
 Exon skipping (Fig 3a). The exon is removed together with the flanking introns from the pre-
mRNA. Exon skipping is the most common AS event in higher eukaryotes. 
 Alternative 3’ start site selection (Fig 3b). An alternative splice site acceptor is recognized 
during the spliceosome assembly 
 Alternative 5’ start site selection (Fig 3c). An alternative splice site donor is recognized 
during the spliceosome assembly 
 Intron retention (Fig 3d). The intron is not spliced out from the pre-mRNA 
 Mutually exclusive splicing (Fig 3e). One of the two exons can be included in the pre-mRNA 
but not both.  
 Alternative promoters (Fig 3f). A gene with an alternative promoter allows starting the 
transcription at a different point 
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 Alternative poly-(A) (Fig 3g). If present, a different poly-(A) can be selected as an alternative 
end point for the transcription. 
It has been estimated that 95% of human multi-exon genes undergo at least one AS event. AS is the 
main mechanism responsible for the great disparity in the size of the human genome and proteome, 
between the 22000 genes and the estimated 100.000 proteins (Pan et al. 2008; McManus & 
Graveley 2011).  
AS is not only the main mechanism responsible for protein diversity but is also responsible for the  
regulation, localisation, and function of proteins and for controlling gene expression levels via 
nonsense mediated decay (Wang et al. 2008; Licatalosi & Darnell 2010). 
Alternative splicing regulation 
The spliceosome complex alone is not sufficient to regulate AS. The recognition of the exon is 
mediated by additional elements: (i) the cis-regulatory elements and (ii) the trans-regulatory 
factors. Cis-regulatory elements are sequences of approximately 4-8 nucleotides located in the 
exons or in the neighbour introns that favour the inclusion or the exclusion of an exon in the mature 
mRNA. These splicing regulatory elements (SREs) can be classified as: (i) exonic splicing enhancers 
(ESEs) or silencers (ESSs) if they are located in the exonic region and promote the exon inclusion or 
exclusion respectively, (ii) and as intronic splicing enhancers (ISEs) or silencers (ISSs) if they are 
located in an intronic region and promote or inhibit usage of adjacent splice sites or exons (Wang & 
Burge 2008). SREs act as a signal to recruit the trans-regulatory factors. Trans-regulatory factors are 
RBPs that recognize the cis-regulatory elements and orchestrate the AS events of the transcript. The 
activity of the SREs depends on the location within the pre-mRNA, the same SRE can function as an 
enhancer or silencer depending on whether SREs are located in an intronic or in an exonic region 
(Wang et al. 2008) (Fig. 4). Additionally, the majority of RBPs are able to recognize and bind to 
degenerate SREs, suggesting flexibility in RBPs recognition. The complex interplay between the cis-
regulatory sequences and their recognition by the RBPs allows promoting or inhibiting AS.   
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Given the complexity of the AS regulation and of the spliceosome assembly, it is not surprising that 
AS is prone to error due to the huge number of factors involved, a disruption of which can lead to a 
wide range of diseases (Cieply & Carstens 2015; Lara-Pezzi et al. 2013).  
 
Figure 4: Cis-regulatory elements and trans-regulatory factors regulate alternative splicing. Adapted from (Lara-Pezzi et al. 2013) 
High throughput sequencing 
After (alternative) splicing is completed, RBPs export the mRNA molecules from the nucleus to the 
cytoplasm, precisely into the ribosomes, where they are potentially translated into proteins. The 
mRNA molecules, hence, play a crucial role since they act as an intermediate between the genome 
and the proteome. Quantifying the abundance of each mRNA is fundamental to fully understand 
the molecular mechanisms underlying a phenotype, for this reason, the high-throughput 
sequencing (HTS) methods are, nowadays, widely used. Currently, HTS platforms produce terabytes 
of biological data in a single run. Manually interpreting the results is unfeasible, thus the natural 
next step would be to develop a computational approach to provide a better biological 
interpretation of the generated dataset. This raises three important issues related to: 
• the interpretation and management of the information, due to the huge amount of data 
produced 
• the integration of the large list of data with different databases in order to have a broad view 
and a deeper understanding of the datasets under investigation. 
• the development of reliable automatic approaches for the analysis of the data 
The typical approach employed to interpret a large genes/proteins list typically involves over-
representation analysis (ORA) techniques for identifying candidate genes or gene products 
(proteins) representative of the underlying biological process (Huang et al. 2009). The major 
RBP RBP 
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limitation of these tools is that each gene/protein is treated as an isolated entity, therefore the 
biological information contained in the molecular interaction network underlying the 
genes/proteins set of interest is usually not considered. Since proteins do not act in isolation, most 
of their functions and processes are influenced by the neighbouring polypeptide (von Mering et al. 
2002). Hence shift the ORA at the interaction network level can help to shed light on new biological 
processes (Gonzalez & Kann 2012). 
Protein interactions 
Proteins are fundamental for many biological processes inside and outside the cell, including 
transport of ions molecules and macromolecules across the membrane, accelerating chemical 
reactions, transmitting the information from DNA to the RNA, mediating the transduction of signals 
and much more. Most of these processes are rarely carried out by a single protein but require the 
interaction of many of them. The interaction occurs when two protein interfaces come in contact 
with each other and generate a weak intermolecular force, like hydrogen bond, salt bridge, ionic 
interactions and/or a generic van der Waal's force (Jones & Thornton 1996a).  
Types of interaction 
It has been observed that proteins involved in the same biological process often tend to interact 
with each other (von Mering et al. 2002). The analysis of protein-protein interactions (PPIs) is 
fundamental to understand the molecular mechanisms and functionality of cellular processes. 
Interactions between two proteins can be classified as physical or logical. Physical interaction occurs 
when two or more proteins interact physically forming, for example, a stable complex (Jones & 
Thornton 1996b). Logical interaction or functional association occurs when one or more proteins 
affect the behaviour of other proteins. Examples of logical interaction are the metabolic pathways 
or proteins that are part of a complex without being in direct contact (Huynen et al. 2000).   
Detection methods 
PPIs can be detected through different experimental methods. These methods are classified into 
two main categories:  
 Small scale methods, designed to identify a small number of interactions. These methods 
usually detect a single binary interaction between two proteins 
 High-throughput methods designed to detect large-scale protein interactions; in this case, 
the methods isolate a set of proteins that act as a complex. 
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In the 1980’s and 1990’s, most PPIs were detected via small-scale methods. These methods 
investigate only a little set of proteins of interest. The classical approach made use of X-ray 
crystallography to find proteins that were co-crystallized in pairs. Few PPIs were found using this 
approach because it is very difficult to crystallize a protein, let alone a complex of proteins. In the 
last decade, the advent of high-throughput methods allowed collecting a huge amount of 
interaction data. These methods rely on bait-prey interactions. A bait protein is a protein used to 
“catch” and identify one or more interaction partners (prey proteins). High-throughput methods 
generate a huge quantity of data in a single run, at the cost of limited accuracy. For example, the 
high-throughput yeast two-hybrid (Y2H) assays are ∼50% reliable (Sprinzak et al. 2003).  
Availability of protein-protein interaction data 
PPIs data are collected in several public available databases in the form of a binary interaction. The 
number of protein interaction data available on each database is variable also within the same 
species. The variation mainly depends on the level of curation and on the methods adopted by each 
database to assess the interaction reliability. Some of them, like IntAct (Orchard et al. 2014) 
(www.intact.com), require two different experiments to assess a single interaction, others like 
STRING (Szklarczyk et al. 2015) are less restrictive and take advantage of automatic text mining 
techniques. 
Additionally, the format in which the molecular interaction data is stored depends on the database. 
The lack of an unified standard had delayed the study of PPI and had not permitted the integration 
of available protein interaction data. Recently, the Proteomics Standards Initiative Molecular 
Interaction (PSI-MI) standard (Kerrien et al. 2007) has emerged and is being adopted by the majority 
of the PPI databases. The PSI-MI standard defined a common schema permitting to standardize the 
molecular interaction data in a common format. Furthermore, adopting the PSI-MI standard allows 
sharing and synchronizing data between different databases. 
Protein-Protein interaction networks 
Before the advent of high-throughput techniques, most research efforts were focused on single 
molecules (e.g. genes). The rapid emergence of high-throughput techniques led to a massive 
production of PPI data. These techniques allowed to study several biological processes 
simultaneously and in an integrated manner, leading to what is called ‘system biology’ (Ideker et al. 
2001; Kitano 2002b; Kitano 2002a). Complex networks provide a promising framework for system 
biology investigations. PPIs can be naturally represented by means of networks or graphs. A protein-
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protein interaction network (PIN) can be defined as a complex system of proteins linked by their 
interaction. In a PIN, the nodes represent the proteins and the edges represent the interactions. PIN 
are becoming increasingly large and complex, therefore, the interpretation of the functional 
properties at a large scale is extremely difficult. Hence, there is an increased interest to cluster 
together the proteins with similar function, since it has been observed that proteins involved in the 
same pathway interact together (von Mering et al. 2002; Nabieva et al. 2005). The next natural step 
is to break down the PIN into subnetworks or modules. 
A module is a set of interacting proteins and/or metabolites that, in a co-ordinated way, perform a 
common biological function. In other words, modules are essentially the functional building block 
of the cells (Hartwell et al. 1999; Alon 2003; Barabasi & Oltvai 2004; Spirin & Mirny 2003; Stuart et 
al. 2003). Modules can be further distinguished in complexes and functional modules (Spirin & Mirny 
2003). A complex is defined as a densely-interconnected subgraph of proteins that interact at the 
same place and time forming a single multimolecular machine (e.g. spliceosome). A functional 
module represents a set of proteins that participate in a biological process or in a function, and that 
bind each other at a different time and place (e.g. MAP signal cascade, phases of cell cycle) (Spirin 
& Mirny 2003).  
Network based enrichment analysis 
Standard ORA methods treat each protein as an isolated entity, neglecting the physical interactions 
between the gene/protein sets of interest. For this reason, several computational models have 
recently been developed to shift the functional association analysis at the interaction network level. 
This new class of methods are typically referred to as “network-based enrichment analysis” (NBEA) 
(Laukens et al. 2015). The NBEA methods allow detecting those biological processes that are not 
directly inferable from the annotations of the input protein set, and thus not detectable through an 
ORA. The common objective of all the NBEA methods is to identify modules, the differences lie in 
the algorithmic techniques used to extract the information from the underlying interaction network. 
Several computational approaches have been designed to extract meaningful information from a 
PIN. These methods can be classified into two main categories: 
 Topology based. Algorithms in this category extract the interaction network from the 
starting set of gene/proteins and then assess how much similar/distant they are with 
respect to a reference (among them EnrichNet (Glaab et al. 2012), PathNet (Dutta et al. 
2012), SANTA (Cornish & Markowetz 2014), JEPETTO (Winterhalter et al. 2014)). 
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 Module based. Methods in this category extract modules from the PIN and then test if they 
are involved in a common biological role (among them: PINA (Cowley et al. 2012), FunMod 
(Natale et al. 2014), NET-GE (Di Lena et al. 2015)). 
The most representative and cited methods among the two categories are: EnrichNet and PINA. 
EnrichNet is a web application that provides a network-based integrative analysis. In EnrichNet, the 
set of proteins are mapped on a PIN extracted from STRING (Szklarczyk et al. 2015) database. The 
mapped nodes are used as seeds for a random walk with restart (RWR) procedure. The score 
obtained from RWR is converted into a distance vector from all the reference pathways. The 
distance measures the associations between the input protein set and the reference pathways or 
processes. The output of EnrichNet is a ranking table of pathways or biological processes associated 
with the distance. 
Protein Interaction Network Analysis (PINA) is a web application collecting pre-identified modules 
detected by the molecular complex detection (MCODE) (Bader & Hogue 2003) algorithm and by the 
Markov clustering (MCL) (van Dongen & Abreu-Goodger 2012) algorithm. The MCODE algorithm is 
used to detect small and dense interconnected regions of proteins that should represent complexes 
of proteins, the MCL algorithm is used to identify large and loosely interconnected regions that 
should represent a pathway. Each module identified by PINA is annotated through a standard ORA 
with terms derived from Gene Ontology (Huntley et al. 2015), KEGG (Kanehisa et al. 2012), and 
PFAM (Finn et al. 2014). PINA maps the input proteins to one or more pre-computed modules and 
selects those that are overrepresented. The annotation of the overrepresented module is then 
transferred to the input proteins. 
All these methods, present their drawbacks and advantages. Apart from EnrichNet, these methods 
do not take into consideration the potential tissue-specific expression of the proteins. However, 
EnrichNet provides only the scores to measure the similarities between the input proteins list and 
the reference pathways but does not provide information about the statistical significance of the 
scores. Additionally, apart from NET-GE, the modules extracted with NBEA approaches are not 
function-specific, meaning that they rely only on statistics or topology of the network to find the 
interaction partners but do not check whether two interacting proteins participate in similar 
processes. To our knowledge there is no tool that combines the advantages of topology-based 
methods and of the modules-based methods. 
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The main objectives of this thesis included the development of the necessary tools and algorithms 
for the study of post-transcriptional regulation in the context of myocardial infarction in four 
different cell types (cardiomyocytes, fibroblasts, endothelial cells, and macrophages) at three time 
points and the development of a new functional enrichment analysis technique. To accomplish 
these aims, we define the following specific objectives: 
1) To develop a central and coherent repository that integrates all the RBP-RNA interactions that 
are currently sparse through different repositories.  
2) To identify the alternatively spliced transcripts after myocardial infarction in the four cell types 
at different time points 
3) To identify the motifs and RBPs that regulate the alternative splicing events in the pig infarcted 
myocardium 
4) To develop a new data-driven functional enrichment analysis method to extract further and 
more specific biological processes and functions from a genes/proteins list 
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ATtRACT - A daTabase of RNA binding proteins and AssoCiated moTifs 
Available databases: direct and indirect sources of information 
At the time this work was performed, four were the databases expressly designed for compiling 
information on RBPs and their binding sites:  
 RBPDB (Cook et al. 2011) is a collection of experimentally validated RBPs and associated 
binding sites linked to a reference in literature 
 CISBP-RNA (Ray et al. 2013) contains RBPs and binding sites extracted from in vitro 
RNAcompete experiments.  
 SpliceAid-F (Giulietti et al. 2013) is a database of human splicing factor extracted from 
literature 
 ASD (Stamm et al. 2006) database is no longer maintained. At the present time, the data are 
available only in a text format file and as a consequence is difficult to search, interrogate and 
analyse the records. 
Among these already available databases, a significant portion of information is available in Protein 
Data Bank (PDB) (Rose et al. 2015) in the form of co-crystallized structures of protein RNA-
complexes. At the time, only RBPDB and SpliceAid-F included a limited number of motifs extracted 
from RBP-RNA complexes data available in PDB and were attained via literature mining. 
ATtRACT: integrating different sources of information together 
The data available in RBPDB, CISBP-RNA and SpliceAid-F databases were extracted and integrated 
to populate ATtRACT. Each entry, in ATtRACT, corresponds to a RBP and to its associated binding 
sites. Each entry was, furthermore, annotated with the following fields: the official gene name and 
its synonyms, the gene identifier, the motif associated to the RBP, the experiment performed for 
the detection of the motif, the PubMed identifier and the domains associated to the RBP according 
to PFAM  or InterPro (Mitchell et al. 2015) annotations. Additionally, the GO terms were integrated 
in ATtRACT. GO annotations allow identifying the molecular process, the biological function, and the 
cellular component in which the RBPs are involved and at the same time making unnecessary 
traversing several sources of information to get the desired information. 
Another source of information was the ASD database which was available only as a text file. We 
integrated the last release of ASD database in order to make the entries again accessible to the 
public through ATtRACT. Moreover, we updated the data available in ASD data file and completed 
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the information needed to fill in the fields present in ATtRACT but missing in the ASD database. An 
overview of the data available in attract is shown in Fig 5. 
 
Figure 5: ATtRACT database. (A) Data flows in ATtRACT database. ATtRACT integrates data from SpliceAidF, CISBP-RNA and RBPDB. 
Moreover, 192 novel motifs, not present in any other database, were extracted from PDB and included in ATtRACT. ATtRACT also 
integrates Gene Ontology annotation.  
ATtRACT: standardization  
Inconsistency in nomenclature and annotation is one of the major issues of the last years in life 
science and big data. The RBPDB, CISBP-RNA, SpliceAid-F and ASD databases, all suffer from 
ambiguous gene notation. They are not coherent in terms of reference gene names and/or gene 
identifiers. For example, the Human CELF1 binding protein is named CUGBP1 in SpliceAid-F as well 
as in RBPDB and, CELF1 in CISBP-RNA. In ATtRACT, the RBPs gene names and identifiers were 
changed according to UniProt (Anon 2015) official names allowing to reduce the proliferation of the 
different gene names and duplicated entries. Furthermore, we updated, when available, the gene 
identifiers according to the last version of Ensembl (Flicek et al. 2014), Xenbase (Karpinka et al. 2014) 
or European Nucleotide Archive (Leinonen et al. 2011). 
Integrating the RBP-RNA interactions in Protein Data Bank data 
PDB is a repository of 3D protein structures and molecular complexes. A total of 236 proteins 
structures of RBP-RNA complexes, excluding the ribosomes and prokaryotes, were available in PDB 
(release January 2015). The structures available contained at least a RNA-protein complex and were 
not included in RBPDB and SpliceAid-F databases. The experimental methods used for the detection 
of protein-RNA contacts were: Nuclear Magnetic Resonance (NMR), electron microscopy and X-ray 
crystallography with a resolution better than 3.9 Å. To extract information from all these complexes 
we developed a pipeline to obtain RNA sequence motifs from the structural information stored in 
PDB experiments. RPBs-RNA complexes are bound together thanks to two types of interactions: the 
van der Walls forces and the hydrogen bonds (Jones et al. 2001). Since it is not possible to detect 
the hydrogen bond in the X-ray crystallographic structure, we employed the HBPLUS (McDonald & 
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Thornton 1994) program to assign the hydrogen bond to the X-ray crystallographic data. We used 
the NUCPLOT (Luscombe et al. 1997) program to identify amino acids-RNA contacts. We used a 
distance-based criterion to identify the intermolecular forces involved in the protein-RNA complex 
structures: 
 An hydrogen bond is detected if the distance between the RNA and the protein is less than 
3.0 Å. 
 A van der Walls interaction takes places if the distance between the RNA and the protein is 
less than 3.9 Å. 
We considered a motif as detected if four or more contiguous nucleotides satisfied the distance 
criterion defined previously and interacted with any atom of the RBP. We extracted 256 motifs from 
110 different RBPs, out of which 192 were novel motifs not available in any other database. 
To test the reliability of our method, we performed an ungapped alignment between the motifs 
extracted from PDB and the motifs belonging to the same RBP and verified by another type of 
experiment. We aligned 93 motifs out of 256, belonging to 43 RBPs. Forty-eight motifs (51.6%) were 
perfectly aligned, 27 (29%) differ only in one nucleotide, 4 (4.3%) differ in two nucleotides, the 
remaining 14 motifs (15.1% of the total) differ in more than two nucleotides. For the motifs that 
differ for more than two nucleotides we mined the literature and we found evidence that 13 motifs 
out of 14 were correct even if they were completely different from the motif confirmed with another 
type of experiment (see supplementary Annex I).  
Quality score 
RBP-RNA interactions are detected with different experiments and each one with a different level 
of confidence. For this reason, in ATtRACT a quality score is implemented. The purpose of quality 
score was to evaluate the binding affinity between RBPs and binding sites. SELEX and RNAcompete 
experiments identify winner sequences, i.e. sequences with a strong preference to bind to RBPs. 
The functional motif is assessed through the alignment of winner sequences.  The result of the 
alignment is often represented through IUPAC ambiguous notation (Anon 1986) and shows the most 
frequent nucleotides found at each position. This representation has clear limitations because each 
position is not evaluated quantitatively (Staden et al. 1982) since each nucleotide is considered as 
equally likely. In AEDB and SpliceAid-F databases, the motifs assessed by SELEX or RNAcompete 
experiments are considered equally likely; therefore, it is not possible to evaluate the binding 
affinity between RBPs and motifs. To solve this problem, we manually extracted from the literature 
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the winner sequences and aligned them in order to represent the binding preference through a 
position-specific probability matrix (PPM). If the winner sequences were not annotated, the PPM is 
generated considering the IUPAC letter encoding for more than one nucleotide as equally likely. 
In mathematical terms, the score S of a matrix M for a motif m of length l is defined as: 
𝑆 =  ∏ 𝑃(𝑚𝑖|𝑀)
𝑙
𝑖=1
 
where P(𝑚𝑖|𝑀) is the probability of observing the nucleotide m in position l in the PPM matrix. The 
quality score represented the probability of observing a given motif within the experiment. Note 
that each motif in ATtRACT is associated to a PPM. For this reason and according to the definition 
of quality score, the motifs coming from single sequence experiments, such as UV cross-linking or 
EMSA, have a quality score equal to 1.0, since it is possible to assess only one motif in the 
experiment. 
Sequence scan 
Scanning the sequences searching for potential binding motifs is currently possible only for RBPDB 
and CISBP-RNA databases. The limitation of both databases lies in in the sequences length that is 
possible to scan and in the number of motifs available. 
The Burrows-Wheeler transform (BWT) algorithm (Burrows & Wheeler 1994) is integrated into 
ATtRACT. The BWT algorithm allows to scan the sequences searching for those motifs that perfectly 
match a given sequence or set of sequences. The input file can be a FASTA or multi-FASTA file of 
20000 nucleotides maximum. The BWT currently represents one the most efficient algorithms and 
is widely used by the majority of the first generation NGS algorithms to perfectly align the reads to 
the transcriptome or to the genome (Li & Durbin 2010; Li & Homer 2010); In a very short time, BWT 
scans the input sequences and detects the positions of any or a subset of motifs selected by the 
user, through a perfect match comparison. Additionally, since the number of motifs available in 
ATtRACT greatly exceeded the ones available in the other databases and because of their small 
length, it was very easy to find many of those motifs in any input sequence provided. In order to 
assess the possible biological relevance, we provided a log-odds scores. Three log-odds scores are 
assigned to each motif of the following species since they are the most represented species in 
ATtRACT database: Caenorhabditis Elegans, Drosophila Melanogaster, Homo Sapiens, Mus 
Musculus, Saccharomyces Cerevisiae and Xenopus. To compute the log-odd score, we introduced 
the concept of genomic functional context. The genomic functional context is a collection of three 
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distinct datasets each one belonging to a species specific genomic region. Each dataset is composed 
respectively of the sequences of:  
 all the exons plus 250 nucleotides upstream and downstream 
 all the introns 
 all the coding sequences.  
The log-odd score is defined as the ratio between the probability of locating the motif in the input 
sequence and the probability of finding the same motif in any of the genomic functional context of 
the reference species. Therefore, a log-odd score greater than 0 means that the probability of 
finding the motif is greater in the input sequence with respect to the corresponding genomic 
functional context and vice versa if less than 0. 
In mathematical terms, the score was calculated in the following way: 
Let M = [m1, m2, m3... mn] be the set of the motifs present in the database. 
We defined the genomic functional context GFC = [exon±250, intron, CDS] as the collection of 
distinct datasets containing respectively the sequences extracted from all exons plus 250 
nucleotides upstream and downstream, all introns and all coding sequences of the reference 
organism. 
S [GFC] = [s1, s2 ... sn] where s1, s2 ... sn were the sequences in the reference organism that represent 
the genomic functional context. I.e. S [intron_human] represented all introns in human 
CS[GFC] = [cm1,cm2,cm3,...,cmn] where cm1,cm2,cm3,...,cmn were the occurrences of 
motifs m1,m2,m3,...,mn in S [GFC]  
Let s be an input sequence of length ls and mx ∈ M a motif of length lm of multiplicity t found in the 
input sequence. The log odd ratio was defined as: 
𝑂𝑅𝑆[𝐺𝐹𝐶] =  log2
𝑂𝑏𝑠
𝐸𝑥𝑝𝑆 [𝐺𝐹𝐶]
 
where Obs was defined as:  
𝑂𝑏𝑠 =  
𝑡
𝑙𝑠 −  𝑙𝑚 +  1
 
𝐸𝑥𝑝𝑠[𝐺𝐹𝐶] =  
𝑐𝑚𝑥
∑ [ 𝑙𝑒𝑛 (𝑠𝑖
[𝐺𝐹𝐶]) −  𝑙 𝑚 + 1]
𝑛
𝑖=1
 
Where 𝑙𝑒𝑛 (𝑠𝑖
[ 𝐺𝐹𝐶]) was the length of the ith sequence in S [GFC] 
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MEME and Tomtom 
ATtRACT integrated a pipeline to discover motifs that occur frequently in a set of sequences and 
compare them with the ones present in the ATtRACT database. For this aim,  MEME (Bailey et al. 
2009) and Tomtom (Gupta et al. 2007) programs were integrated into ATtRACT. MEME adopts an 
extension of the expectation maximization algorithm to produce a statistical model that permits to 
find a relationship between possibly related unaligned sequences. To evaluate whether a de novo 
motif, enriched in a set of sequences, looks like to any other motif present in the ATtRACT database, 
the Tomtom algorithm is integrated into the pipeline. A score is assigned by Tomtom to each de 
novo motif, found by MEME, and based on the expected value (E-value). The E-value describes the 
number of hits one can expect by chance in a database of a particular size. The closer to zero the E-
value, the more plausible the match is. The E-Value is strongly correlated with the database’s size, 
for this reason ATtRACT allows to extract a subset of the database according to: (i) the length of the 
motif, (ii) the experiment assessed, (iii) the organism, and (iv) the domain, in order to fine tune the 
research and increase the E-Value. 
Implementation details 
The algorithms in ATtRACT were implemented in python 2.7 (https://www.python.org) and C/C++. 
To store the information, managing and organizing the database, the SQLite database 
(http://www.sqlite.org) was adopted. The web2py (http://www.web2py.com) framework and 
bootstrap (http://getbootstrap.com) framework were used for designing and developing the web 
interface and for interfacing with the database.  Nginx (http://nginx.org) handles the user’s request. 
The plots were implemented using the D3js (http://d3js.org) and highcharts 
(http://www.highcharts.com) libraries. The tables displaying the results were implemented using 
the javascript plug-in called DataTables (http://www.datatables.net). The logos were generated 
through WebLogo3 software (http://weblogo.threeplusone.com) 
Analysis and regulation of alternative splicing in the pig infarcted 
myocardium 
RNA extraction 
Large white pigs (Sus scrofa) were used for the experiments, since they represent a good 
translational animal model. Myocardial ischemia was induced via balloon occlusion for 45 minutes. 
The balloon was inserted in the left ascending coronary artery and inflated. Forty-five minutes later 
the balloon was deflated and the normal circulation flow was restored again. The pigs were 
sacrificed at day 0 (no infarct), 3 days and 7 days post myocardial infarction by the administration 
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of potassium chloride. From the infarcted tissue area, a piece of tissue was minced and digested 
with collagenase. The enzyme digestion supernatant was collected in several rounds of digestion, 
collagenase was inactivated with fetal calf serum and cardiomyocytes (CMs) were decanted by 
gravity. ECs, FBs and MFs were isolated form the cell supernatant by fluorescence-activated cell 
sorting (FACS) using specific antibodies for each cell type. For each cell type, total RNA was 
extracted, quantified and sequenced by the CNIC Genomics unit.  
Proteins identification 
Protein extracts were obtained by cell lysis. Protein extracts for each time-point were quantified 
and pooled according to their concentration. Samples were subjected to tryptic digestion and the 
resulting peptides were labelled for relative quantification (iTRAQ) and separated. The fractionated 
peptides were analysed by nano-liquid chromatography-tandem mass spectrometry (nanoLC-
MS/MS) using a Q-Exactive hybrid quadrupole orbitrap mass spectrometer (Thermo Scientific). 
Protein identification was performed by the CNIC Proteomics unit using the SEQUEST HT algorithm 
integrated in Proteome Discoverer 2.1 (Thermo Scientific). Peptides were identified from MS/MS 
data using the probability ratio method (Martinez-Bartolome et al. 2008). False discovery rate (FDR) 
of peptide identifications was calculated by the refined method (Bonzon-Kulichenko et al. 2015, 
Navarro et al. 2009). 
RNA-Seq:  how the reads were generated 
RNA-Seq is a next generation sequencing (NGS) method that allows sequencing the transcriptome 
in a sample. RNA-Seq is, currently, widely used to analyse gene expression and alternative splicing. 
The protocol used for sequencing consisted of the following steps: (i) the poly-adenylated RNA was 
extracted from each cell types and from each time point; (ii) the RNA was converted into cDNA and 
fragmented; (iii) the fragments were amplified and the adapters were ligated to the fragments; 
finally, (iv) the cDNA was sequenced. Samples were sequenced in an Illumina HiSeq 2500, which 
produced 61 nucleotides long reads.  
RNA-Seq analysis: removing the adaptors and low quality reads 
The output of the sequencing machine is typically a list of raw sequences data in FastQ format. A 
quality control check was performed through the FastQC (Wolf, 2013) program to check the quality 
of the reads. Initially, we got an average of 85,052,976 reads per cell type and time point (Fig 6). The 
CMs at day 0 showed the fewest reads (51,983,142). Conversely, the best yield was obtained from 
CMs at day 3 (100,174,650). 
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We used the Cutadapt (Martin 2011) program to trim the raw sequences data and remove the 
adapter. Additionally, those reads shorter than 30 nucleotides were removed. After the trimming 
step, 0.002% of the reads, on average, per all the cell types and all the time points were removed, 
producing reads of length ranging from 30-61 nucleotides. The FastQC program was run again to 
check that the qualities of the reads were improved. 
 
Figure 6:  Number of reads per cell type and time point 
The trimmed sequences were mapped to the pig reference transcriptome (reference build: Sus 
scrofa 10.2.73 http://www.ncbi.nlm.nih.gov/assembly/304498/ ). We chose the RSEM (Li & Dewey 
2011) algorithm to align the reads, given that recent benchmarks suggest that RSEM outperforms 
other available tools in the detection of the isoform expression levels (Dapas et al. 2016).  
Large scale data analysis 
Typically, the output of genome-wide studies is a list of thousands of genes associated with values 
representing their expression. The biological interpretation of these lists is challenging and led to a 
great demand for methods to analyse a large amount of data generated in an automatic way.  
A widely-used technique for the analysis of the datasets is by means of ORA. Several techniques are 
available, but all of them try to assess, with a statistical test, whether a gene/protein set is 
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overrepresented in a reference list of known gene/protein sets. Gene Ontology database is widely 
used as a source of annotated gene/protein sets and is commonly used for the ORA. 
Gene ontology database 
Ontologies, termed as a set of concepts within a domain, have gained increasing attention in the 
recent years as tools for representing knowledge. According to Gruber’s (Gruber 1993) definition, 
an ontology is “an explicit specification of a conceptualization”. Ontologies in bioinformatics play a 
key role because provide a source of standardized nomenclature terms. The Gene Ontology project 
concentrates its efforts to provide species-independent descriptions of gene products through a 
controlled vocabulary and to define the relationships between different terms (GO terms). 
GO terms are organised in a direct acyclic graph such that the level of specificity of the terms 
increases while traversing the graph from the root to the leaves. GO vocabulary is also subdivided 
into three domains: 
 Cellular Component (CC) – describes the part of a cell or its extracellular environment in 
which the gene product is localised 
 Molecular Function (MFu) – describes the gene product’s elemental activities at the 
molecular level 
 Biological Process (BP) – describes the events in which the gene product is involved 
Researchers are often interested to know whether the output of their experiments shares some 
characteristics with a known set of genes/proteins. ORA method helps investigators to detect genes 
or proteins annotations significantly enriched within a target set of genes of interest, with respect 
to a background set.  
Fisher’s exact test and Bonferroni correction 
To proceed with the testing of data, some hypotheses should be made. In a testing problem, two 
different and complementary hypotheses are formulated, the null hypothesis (H0) and the 
alternative hypothesis (H1). 
The purpose of the hypothesis test is to establish if there is some experimental evidence that 
supports the rejection of the null hypothesis, setting a significance level to a certain significance 
threshold (α). The p-value measures the strength of the evidence against the null hypothesis in 
favour of the alternative hypothesis. The comparison of the p-value with α tells if the null hypothesis 
should be rejected. 
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Fisher’s exact test is a statistical significance test for categorical data.  This non-parametric test is 
performed to verify if categorical data is compatible with the null hypothesis (H0). In Fisher’s test, 
categorical variables are grouped into a contingency table and represent the frequency sample of 
the variables. 
Fisher demonstrated that the probability of observing the sample in a contingency table follows a 
hypergeometric distribution and in case of true null hypothesis is equal to: 
𝑝 =
(
𝑎 + 𝑏
𝑎
) (
𝑐 + 𝑑
𝑐
)
(
𝑛
𝑎 + 𝑐
)
=
(𝑎 + 𝑏)! (𝑐 + 𝑑)! (𝑎 + 𝑐)! (𝑏 + 𝑑)!
𝑛! 𝑎! 𝑏! 𝑐! 𝑑!
 
Where a, b, c, d are the values of the contingency table and p is the probability of observing the 
samples a, b, c, d if the null hypothesis is true. 
This procedure is valid if and only if the number of the hypotheses tested is equal to one. 
When an experiment is performed, usually many hypotheses are considered; hence, adjustment of 
p-value is needed to reduce the probability of obtaining false positive results when multiple tests 
are executed on a single data set. 
With the Bonferroni correction, the adjusted p-value is equal to: 
𝑃𝐼 =
𝑃
𝑘
  
Where k is the number of tested hypotheses. 
Bonferroni’s correction is very stringent; hence, the risk is to throw away real enrichments. 
Identification of isoform switches 
A gene can give rise to different transcripts, the overall expression of a gene may remain constant 
between two conditions while the relative abundance of individual transcripts may change resulting 
in an isoform switching.  
To detect the potential isoform switches we developed a pipeline inheriting some of the steps 
implemented in cufflinks (Trapnell et al. 2010b).  The employed pipeline is composed of three main 
steps: 
1) For the same gene and between two conditions, calculate the relative abundance distribution 
of the transcripts. 
2) Calculate the Jensen-Shannon distance of the two transcripts distributions generated previously. 
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3) Rank the genes according to the Jensen-Shannon distance calculated previously and select only 
those genes lying over the 95th percentile. 
The pipeline selected only those genes showing extreme changes in the abundance percentage of 
the transcripts. To proper select the transcripts undergoing isoform switching, we further selected 
the transcripts according to the criteria that are described in the paragraph isoform switching 
detection and filtering. 
The 'IsoPct' field in RSEM output represents the transcript isoform percentage, in other words, the 
ratio between transcript’s abundance and the gene's abundance.   
If only one isoform is present, the isoform percentage is set to 100% and we excluded all these 
transcripts. 
An example of how the isoform percentage is calculated is shown in Fig 7. 
The Jensen-Shannon distance 
The square root of the Jensen-Shannon divergence is a commonly used measure (Trapnell et al. 
2010a) to determine which genes were significantly changed (e.g. isoform switches) among two 
conditions. The JSD is defined as: 
𝐽𝑆𝐷(𝑃||𝑄) =  
1
2
 𝐷(𝑃||𝑀) +  
1
2
 𝐷(𝑄||𝑀)      
𝑤ℎ𝑒𝑟𝑒: 𝑀 =
1
2
 (𝑃 + 𝑄) 
and P and Q represent the isoforms percentage distributions of the transcripts of the same gene in 
two different conditions. Following the example in Fig 7 P = [0.5, 0.2, 0.3] and Q = [0.06, 0.56, 0.38] 
and the JSD = 0.46. 
The output of the Jansen-Shannon distance (JSD) is a number comprised between 0 and 1 that 
measures the similarity between the isoform percentage distributions in two conditions. A higher 
value of the JSD is correlated with a higher probability of observing changes in the transcript 
abundance percentages between two conditions. In other words, under the null hypotheses of no 
transcripts abundance percentage change between two conditions, the Jensen-Shannon distance is 
equal to 0.  
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Figure 7: How the isoform percentage is calculated. The expression of Gene A is equal to 50 TPM in condition 1 and to 80 TPM in 
condition 2. The TPM are of Gene A are divided across the 3 transcripts. The transcript percentage is the ratio between the gene TPM 
and the transcript TPM in the two conditions. The values of the isoform percentage represent the isoform percentage distributions 
employed to calculate the JSD. 
Isoform switching detection and filtering 
To guarantee a highly dissimilar expression between the transcripts in two conditions, we selected 
only those genes whose JSD overcame the 95th percentile.  To detect an isoform switch, each gene 
was associated with at least two transcripts.  The transcripts were treated pairwise if a gene was 
transcribed in more than two transcripts. 
So far the pipeline acted at the gene level. To properly select the transcripts undergoing an isoform 
switch the following criteria must be satisfied: 
 transcripts whose expression is less than 1 TPM in at least one condition were not considered 
 the log fold change of the transcripts must be opposite because we wanted to detect a 
switch of the isoform in two conditions. We used the following formula:  
log (
𝑇𝑟1𝐶𝑜𝑛𝑑 2
𝑇𝑟1𝐶𝑜𝑛𝑑 1
) > 0 and log (
𝑇𝑟2𝐶𝑜𝑛𝑑 2
𝑇𝑟2𝐶𝑜𝑛𝑑 1
) < 0 or vice versa 
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 Additionally, to avoid the detection of very small changes in isoform switching, the 
difference in isoform percentage of the same transcript in two conditions must be greater 
than or equal to 10% in absolute value. In mathematical terms: 
|(𝑇𝑟1𝐶𝑜𝑛𝑑 1 − 𝑇𝑟1𝐶𝑜𝑛𝑑 2)|>=0.1 and |(𝑇𝑟2𝐶𝑜𝑛𝑑 1 − 𝑇𝑟2𝐶𝑜𝑛𝑑 2)|>=0.1 
Regulation of alternative splicing and validation at proteomic level 
Alternative splicing is regulated by trans-regulatory splicing factors, a subclass of RBPs that 
recognise short sequences located upstream and downstream of the exon start site. To detect those 
sequences and the associated splicing factors, we employed a pipeline similar to the one designed 
in ATtRACT. MEME was adopted to find ungapped motifs that were overrepresented in a set of 
sequences. Subsequently, Tomtom assessed whether the overrepresented motifs found by MEME 
were similar to the ones available in ATtRACT. 
We run 12 different sessions of MEME one for each possible cell type and contrast. (Fig 8) (4 cell 
types: CMs, FBs, ECs and MFs, and three possible time courses: day 3 vs day 0, day 7 vs day 0, day 7 
vs day 3). The zoops model was employed to assess the overrepresentation of motifs in a set of 
sequences, the zoops model assumes that each sequence may contain at most one occurrence of 
each motif. MEME was fed with sequences extracted from a window of 300 nucleotides upstream 
and downstream (600 nucleotides in total) from all the alternatively spliced exons. Each MEME 
session was characterised by a different set of sequences in input since different sets of alternatively 
spliced transcripts were found in each cell type and at each time point. 
To better characterise the regulatory elements, we selected as background the sequences extracted 
from all the alternative spliced exons in the genome. Subsequently, we employed Tomtom to (i) 
assess whether the motifs found by MEME, with a p-value<0.05, resemble the ones available in 
ATtRACT, and (ii) to select, among all the possible RBPs, the potential splicing regulatory factor. To 
validate our findings, we took advantage of the data available in the proteomic profile. The 
proteomic profile was used to assess whether: 
 the transcripts were translated into proteins  
 the splicing factor was expressed at the protein level. 
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It is important to note that the proteomic profile is less accurate than the transcriptomics profile 
and a large fraction of the proteome is usually not detected (Laukens et al. 2015). Hence, the 
absence of a protein associated with an alternatively spliced transcript at the proteomic level may 
be due to (i) the post-transcriptional regulations or (ii) the impossibility to detect the protein. 
 
Network based enrichment analysis 
ORA methods are nowadays widely used to detect a functional profile of a genes/proteins list. We 
have described above in this section the ORA method (see paragraphs Fisher’s exact test and 
Bonferroni correction). In the following paragraphs, we describe the resources and the algorithms 
employed to develop a novel ORA method that takes advantage of the PIN. We called this method 
MAGNETO: augMented functionAl enrichment analysis throuGh proteiN intEracTion netwOrk. 
The algorithms designed in MAGNETO make intensive use of four databases to: 
 extract the PIN 
 identify the top-level pathways 
 simplify the network according to the tissue protein expression  
 filter the modules according to the top-level pathway annotation. 
Figure 8: Pipeline adopted to detect the regulatory motifs.  Twelve different sessions of MEME one for each possible cell type and 
contrast (4 cell types: CMs, FBs, ECs and MFs, and three possible time courses: day 3 vs day 0, day 7 vs day 0, day 7 vs day 3) were 
run. We fed Tomtom with the results obtain by MEME to assess whether the motifs found by MEME resemble the ones available 
in ATtRACT 
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Databases employed 
Despite the recent advances, the PPI detection methods are affected by high false positive rate 
(Sprinzak et al. 2003), hence it is fundamental that the PPI database contains manually curated 
interactions and that the procedures for the annotation of the experiments are rigidly controlled. 
Currently, there are several databases containing PPI, including STRING (Szklarczyk et al. 2015), 
BioGRID (Breitkreutz et al. 2008) and IntAct (Orchard et al. 2014). The main difference between 
them lies in the quality of the annotation. In this respect, IntAct is one of the most stringent. IntAct 
is an open and freely available database that collects, analyses and stores molecular interaction 
data. The interactions are manually curated and updated very frequently. Furthermore IntAct is a 
member of HUPO Proteomics standards initiative (PSI) (Kerrien et al. 2007), and IMEX (Orchard et 
al. 2012).  
Two are the most widely used manually curated databases of pathways, KEGG (Kanehisa et al. 2012) 
and Reactome (Fabregat et al. 2016). We chose Reactome, because, with respect to KEGG, it 
includes more proteins. There were 6970 annotated proteins in KEGG (release September 2016) and 
10044 in Reactome (version 58). 
Recently, several databases have been developed to assess tissue specific protein expression: 
Human Proteome map (release 29 May 2014)  (Kim et al. 2014), ProteomicsDB (release 23 June 
2016) (Wilhelm et al. 2014), and Human Protein Atlas (version 16) (HPA) (Uhlén et al. 2015). 
Amongst them, the HPA database is the most comprehensive one in terms of tissues composition 
(Table 3).   
Table 3: Tissues composition across three different protein expression databases. Human Protein Atlas is the most comprehensive 
in term of represented tissues. 
 Human proteome map ProteomicsDB Human Protein Atlas 
Tissues 17 33 44 
 
The UniProt-GOA (last release September 2016) (Huntley et al. 2015) database was chosen for the 
GO annotation. UniProt-GOA is a branch of the most famous Gene Ontology database, which has 
become the standard de facto for gene ontologies. 
Protein-Protein Interaction Data: IntAct Database and generation of PPI networks 
IntAct is an open and freely available database whose aim is to collect, analyze and store molecular 
interaction data. All the interaction data in IntAct derive from manually curated literature and have 
been annotated with experimental methods, conditions and interacting domains. 
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Over the years, the IntAct database has grown, with some exception, almost linearly (Fig 9). 
Nowadays it contains 93,856 proteins and 1,071,798 interactions out of which 61% (653,104) are 
binary interactions extracted from over 14,346 publications. Here, we present a brief overview of 
the IntAct database content.  
 
Figure 9: Total number of interactions available in IntAct. The number of interactions increased over time. Adapted from 
http://www.ebi.ac.uk/intact/about/statistics 
The interaction types can be broadly classified into two groups: the physical association (54.9%), 
and the association (36.4%) (Fig 10). 
 
Figure 10: The physical association (54.9%) and the association (36.4%) are the most represented type of interactions in IntAct. 
Adapted from http://www.ebi.ac.uk/intact/about/statistics 
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An interaction is classified as “physical association” if the method captures only two interactors at 
a time (yeast two-hybrid) or it involves purified molecules (NMR or X-ray crystallography). The 
interaction is classified as “association” if multiple interactions are captured at the same time (i.e. 
co-immunoprecipitation, tandem affinity purification). Typically, these methods assess the 
interaction between a bait protein and an n-ary complex of proteins (prey). A common problem of 
the association methods regards the classification of the interaction between the bait and the prey 
since the interactions are annotated in the form of a binary interaction in the database. 
Two different models have been typically employed (Fig 11): 
 In a Matrix expansion model, the molecules in the complex are linked together like in a 
complete graph. If the complex is composed of N proteins, it generates 𝑁× (𝑁 − 1) binary 
interactions. 
 In a Spoke expansion model, the binary interaction is identified only between the bait protein 
and each protein of the n-ary complex. If N is the number of proteins in a complex, N-1 
interactions are generated. 
IntAct employs the spoke expansion method to avoid the proliferation of false positive interactions. 
In MAGNETO, two types of networks were extracted from IntAct (release 27th August 2016) (Table 
4) and take into account the different level of confidence generated by the detection methods: (i) A 
high confidence PIN associated only with the low-throughput experiments (only physical association 
Figure 11:  In this example a tandem affinity purification experiment is performed. The red dot is the bait protein and the others 
are the prey complex. With tne matrix exapansion model the complex is modelled as a complete graph and 15 interactions are 
detected. With the spoke expansion model only the bait interacts with the n-ary complexes and 5 interactions are detected. But, 
in reality,  it may happen that the red protein has only one interactor, which would be the yellow one. Adapted from 
(http://www.ebi.ac.uk/intact/main.xhtml) 
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interactions), and a PIN that includes also the high-throughput experiments (physical association 
and association interactions). 
It is evident that high-throughput experiments and spoke models allow to increase the number of 
edges in the network. This means that considering the IntAct network, a lesser number of nodes 
need to be traversed to connect two different nodes with respect to the IntAct high confidence 
network. 
Table 4: Nodes and edges distribution of the two networks extracted from IntAct. The spoke model and the high throughput 
experiments allow increasing the number of edges. An increased number of edges allows decreasing the number of nodes 
connecting two paths of the network.   
 IntAct High Confidence IntAct  
Nodes 12672 14802 
Edges 60304 102345 
Average degree 9.5 13.8 
 
Tissue specific protein expression database: Human Protein Atlas (HPA) 
The systematic exploration of the human proteome is fundamental to understand how the 
expression of the ~20,000 human protein-coding genes affects the corresponding proteins at the 
tissue level. The HPA database (version 16) contains protein expression data extracted from 44 
different human tissues and organs (Fig 12). To derive the protein expression data, the 
immunohistochemical staining of cell populations in human tissues together with mRNA expression 
data are taken into consideration. Finally, the HPA database evaluates the expression levels of the 
proteins in each tissue with four levels: no expression, low, medium and high. In MAGNETO, each 
protein expression level is associated with a number (no expression=0.01, low=0.33, medium=0.66, 
high=1). We considered the average of the protein expression if the protein is detected in the same 
tissue multiple times (i.e. the same protein is detected high in the adipocytes and low in the 
fibroblasts in liver). 
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Figure 12: The tissues available in HPA and the number of proteins detected in each tissue. The number at the right of the bar 
represents the number of proteins involved in each tissue.  
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Pathways data: Reactome database 
Reactome is a freely available database of manually curated pathways and reactions. In Reactome, 
the pathways are organized in a hierarchical way, meaning that moving down the hierarchy more 
specific biological pathways are found (e.g. signal transduction → signaling by FGFR → signaling by 
FGFR1). In Reactome, the top-level pathways represent the highest level of the hierarchy and are 
associated with a general biological process (e.g. hemostasis, gene expression, signal transduction).  
Figure 13: The 23 top-level pathways available in Reactome. The number at the right of the bar represents the number of proteins 
involved in each of the top-level pathways.  
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The proteins involved in a top-level pathway participate together in a common biological function, 
essentially, they represent a coarse-grained module (CGM). Twenty-four top-level pathways are 
available in Reactome (version V58), of these we excluded the top-level “Disease” pathway because 
all the proteins involved in this pathway are redundant since they are already included in the other 
top-level pathways.  The histogram in Fig 13 shows the number of proteins involved in any of the 23 
top-level pathways.  
Graph theory: basic principles  
PPIs can be naturally represented by means of graphs (network) in which the nodes represent the 
proteins and the edges their interactions. In this following paragraphs, we introduce some concepts 
that will be useful to understand the idea behind of MAGNETO. 
Graphs and sub-graphs: some definitions 
Graphs are mathematical structures, used to model a great variety of problems. A graph G = (V, E) 
is a pair of sets, where V is the set of vertices or nodes {V1, V2…. Vn } and E is a set of edges, such that 
to each element of E correspond a couple of elements of V. 
Definition: H = (W, F) is a sub-graph of G= (V, E) if and only if W ⊆ V andF⊆ E (Fig 14) 
Definition: Given a graph G = (V, E), a path P = (V1,V2) is a set of distinct nodes {V1,V2,…, Vn}, such 
that: 
∃ (𝑉1,𝑉𝑖+1) ∈ 𝐸 ∀ 𝑖 ∈  [1, 𝑝 − 1] 
Shortest path and all pairs shortest Paths  
A path is a sequence of nodes that need to be traversed to connect the target and the source node. 
A path never passes two times over the same edge or node.  
In an undirected graph, the shortest path (SP) di,j  between two nodes Vi  and Vj represents the 
minimum distance connecting two nodes. The distance between two nodes is defined as: 
     {
di,j = {min(Vi, 𝑉j) if the path exist
∞ otherwise
  
 Figure 14: On the left a graph, on the right one of the possible sub graphs extracted from the graph on the left 
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Potentially, there are many paths between two pairs of nodes in a graph. Given a pair of nodes, 
determining all the possible shortest paths connecting them is called all-pairs shortest path (APSP) 
problem. Computing the APSP for large graphs like a PIN is a computationally expensive (O(n3)) task. 
To decrease the computational time, in MAGNETO, we implemented a C++ algorithm based on the 
igraph (http://igraph.org) library, allowing to reduce of several orders of magnitude the time with 
respect to a python based algorithm. 
MAGNETO workflow 
The main aim of MAGNETO is to identify modules, meaning sets of interacting proteins involved in 
a common biological function. To accomplish this task, we adopted a data-driven approach in order 
to combine the advantages of the topology-based methods and module-based methods.  
MAGNETO requires in input a protein list and a tissue chosen from the 44 available in HPA. 
The algorithm developed in MAGNETO involves four main phases: 
1. A preprocessing phase in which the input proteins are mapped into the 23 top-level 
pathways available in Reactome.  
2. A Connecting phase in which MAGNETO extracts, for each of the top-level pathways, the 
Minimal Connecting Network (MCN). I.e. the network composed of the union of all shortest 
paths between each possible pair of proteins. 
3. A Simplification phase in which MAGNETO, removes the paths that are barely expressed in 
the selected tissue. 
4. A Maximization phase in which MAGNETO selects the paths whose annotation is highly 
representative of the CGM. 
Definition: The proteins assigned to a CGM are called seed proteins. 
Preprocessing phase: mapping the seed proteins to Reactome 
During the preprocessing phase, the seed proteins were mapped into the CGMs allowing to define 
coarse-grained groups of proteins involved in the same biological process. It is important to notice 
that a seed protein can be involved and assigned to more than one CGM. Since Reactome contains 
only a small fraction of the human proteome, it could happen that some of the seed proteins remain 
unmapped. To solve this problem, we started from the consideration that since proteins with similar 
functions are involved in the same biological process, then proteins sharing similar biological 
processes should participate in the same CGM. Hence, we extracted a GO profile (GOP) from each 
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of the CGM. The GOP is, essentially, a ranking table representing the probability of finding a BP in 
the CGM. For example, the first 5 GO terms involved in the vesicle-mediated transport CGM are: 
Transport, protein transport, vesicle-mediated transport, receptor-mediated endocytosis, and ER to 
Golgi vesicle-mediated transport. The proteins lacking Reactome annotation are ranked according 
to the GOP probability. For each unmapped protein, 23 scores are generated, one for each CGM. 
The score represents the sum of the probabilities of finding the BPs in which the proteins are 
involved in a CGM. The probabilities are calculated according to the probabilities extracted from 
each one of the GOP profiles. The unmapped protein is assigned to the CGM by selecting the one 
with the highest score, in other words, the higher the score is, the higher is the similarity between 
the biological processes in which the protein is annotated and the biological processes of the CGM. 
Connecting phase: computing the Minimal Connecting Network 
After all the proteins in the input list were assigned to at least a CGM, the connecting phase takes 
place. This phase is the most computationally expensive of the whole MAGNETO workflow. For each 
set of proteins in a CGM, MAGNETO computes the graph constructed by the union of all the shortest 
paths between any possible pair of nodes involved in a CGM. The resulting network is called minimal 
connecting interaction network (MCN). The extraction of the MCN involves two main steps.  
During the first step, MAGNETO computes all the possible combinations of protein pairs in any of 
the CGMs. Formally, given a set S of objects (i.e. the seed proteins in a CGM), how many 
combinations can assume k objects selected from this set. It is a combinatorial problem and the 
number of possible combination of n elements of length k is given by the formula: 
Cn,k = (
n
k
) =
n!
k! (n − k)!
 
Where n is the number of proteins in the CGM, and k is equal to two, corresponding to a protein 
pair. From this procedure, we exclude the CGMs with only one protein. During the second step, 
MAGNETO, for each pair of proteins previously extracted, computes all the possible shortest paths. 
The MCN permits to understand how the proteins involved in the same biological process are 
connected to each other in terms of shortest paths. In other words, the MCN allows highlighting the 
underlying interaction network for each of the CGM. Typically, many MCNs are computed in a single 
run of MAGNETO, the total number depends on how the seed proteins are assigned to the 
respective CGM (Fig 15).  
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Figure 15:The genes/proteins in input are mapped to one or more CGM. Then for each CGM the MCN is computed by the union of 
all the shortest paths of the seed nodes. 
It is important to note that, typically, there are many shortest paths between two seed proteins. 
Additionally, excluding the isolated nodes, the obtained MCN is sub-isomorphic to the original graph 
and constitutes the backbone for the filter phase. 
Simplification phase: filter the paths based on tissue expression 
Even for medium-small protein sets, the MCNs cover a large fraction of the whole interactome and, 
therefore, are not representative of the underlying biological processes. To overcome this problem 
a graph-simplifying (Ruan et al. 2011) procedure is implemented. Simplifying means to eliminate 
“unimportant” nodes and associated edges from the MCN while preserving its most important 
characteristics. 
In MAGNETO, we applied a graph filtering approach with the difference that instead of removing a 
single node at a time, all the nodes connecting the source and the target but not the source and the 
target, are removed in a single run. Initially, the paths that are expressed at low level in the selected 
tissue are removed. 
MAGNETO assigns a value to each node/protein connecting the seed proteins. The node values 
represent the protein expression extracted from the HPA in the tissue selected by the user. If the 
protein expression is missing in the selected tissue, MAGNETO assigns a pseudo value of 0.01. 
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Typically, two seed nodes are connected by many paths, MAGNETO computes the average 
expression for each path. The vector obtained corresponds to the average expression of all the paths 
connecting two seed nodes. The mean of the vector corresponds to the threshold assigned by 
MAGNETO in order to discard those paths that are expressed at a low level in the selected tissue. In 
other words, during the simplification phase, for each pair of proteins of the input list, those paths 
that are the most highly expressed in the selected tissue are selected (Fig 16A).  
 
Figure 16: The red nodes are the seed nodes; the black nodes are the nodes involved in the shortest paths. For each path, the average 
path expression is calculated. The average of the average path expression is the threshold for selecting the paths that are highly 
expressed in the tissue(A). For the remaining paths, the similarity score is computed. The similarity score represents the likelihood 
between the biological processes go terms in the paths and in the CGM. The path with the highest rank is selected (B). 
Maximization phase: filter the paths based on annotation 
The CGM networks obtained previously are further filtered. After the simplification phase, 
potentially, there are still several paths connecting two seed nodes. The aim of the maximization 
phase is to rank each path connecting two seed nodes.  The rank is given by the sum of the 
probabilities of finding the BPs, in which the proteins involved in the path are annotated, in the GOP.  
The selected path is the one that shows the highest rank, i.e. the highest similarity between the 
annotations of the proteins involved in the path and the GOP of the CGM under investigation (Fig 
16B).  
From each of the CGM, a subnetwork extracted from the PIN is obtained. The subnetwork is (i) 
representative of the biological processes that take place in the CGM and (ii) of the tissue-specific 
interactions that occur between the seed proteins.  
Finally, all the nodes extracted from each of the CGM represent the testing set for the ORA. 
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Databases integrated in MAGNETO 
To have a broad view and a deeper understanding of the datasets under investigation, several 
databases were integrated into MAGNETO. They can be grouped into 5 main categories: 
1) Biological pathway databases: 
a) Reactome (Version 58) (Fabregat et al. 2016) 
b) KEGG pathway (Release September 2016)  (Kanehisa et al. 2012) 
2) Drug databases: 
a) KEGG drugs (Release September 2016)   (Kanehisa 2013) 
b) DrugBank (Version 5.0) (Law et al. 2014) 
3) Disease databases 
a) OMIM (Release September 2016)   (Amberger et al. 2015) 
b) Orphanet (Release September 2016) (Davies 2016) 
c) KEGG disease (Release September 2016)   (Kanehisa 2013) 
d) DisGeNet (Release October 2016)   (Queralt-Rosinach et al. 2016) 
4) Toxin database: 
a) T3DB (Version 2.0) (Lim et al. 2010) 
5) Host - Pathogen Interaction database 
a) HPIDB (Version 2.0) (Ammari et al. 2016) 
Magneto performance evaluation 
One of the main challenges common to all the ORA methods regards the assessment of their 
performances. The fact that most of the overrepresented terms can be supported by some 
references in the literature makes the task of evaluating the performance of the ORA methods 
difficult. To compare MAGNETO with ORA we employed the method proposed by Tarca et al. 2012. 
Twenty-one datasets (Table 5), associated with a pathology and for which exist a tissue in HPA, were 
selected from the GEO database (Barrett et al. 2013), each one of these datasets could be associated 
with a target pathway in KEGG database (i.e. the colorectal cancer is the target pathway from all the 
GEO dataset studying colorectal cancer). MAGNETO and the standard ORA method were compared 
in terms of (i) distribution of the -Log(p-values) of the target pathway (the higher the better) and (ii) 
on the ability of the method to rank the target pathway on the top of the overrepresented terms 
list (the lower the better). The rank was normalized between 0 and 100 using the formula: 
𝑟𝑎𝑛𝑘 =
𝑖 ∗ 100
𝑁
 
where i was the rank of the target pathway in the overrepresented list of terms and N is equal to 
214 representing the total number of pathways in KEGG excluding the metabolism pathways. It 
could happen that none of the proteins in the input list is associated with the target pathway, 
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therefore a p-value cannot be provided, in this case, the p-value is equal to 1 and the rank is equal 
to 214. 
Table 5: The 21 pathways selected for the benchmark. The first column represents the GEO ID, the second column represents the 
literature reference (if exists), the third the target pathway and the fourth the associated KEGG id, the fifth column represents the 
tissue were the experiment were performed and the sixth the tissue selected in MAGNETO 
GEOID Pubmed Disease/Target 
pathway 
KEGGID Tissue Tissue in 
MAGNETO 
GSE1297 14769913 Alzheimer’s Disease hsa05010 Hippocampal CA1 Cerebral cortex 
GSE5281 17077275 Alzheimer’s Disease hsa05010 Brain, Entorhinal 
Cortex 
Cerebral cortex 
GSE5281 17077275 Alzheimer’s Disease hsa05010 Brain, hippocampus hippocampus 
GSE5281 17077275 Alzheimer’s Disease hsa05010 Brain, Primary visual 
cortex 
Cerebral cortex 
GSE20291 15965975 Parkinson’s disease hsa05012 Postmortem brain 
putamen 
Cerebral cortex 
GSE4107 17317818 Colorectal Cancer hsa05210 Mucosa Colon 
GSE8671 18171984 Colorectal Cancer hsa05210 Colon Colon 
GSE9348 20143136 Colorectal Cancer hsa05210 Colon Colon 
GSE14762 19252501 Renal Cancer hsa05211 Kidney Kidney 
GSE781 14641932 Renal Cancer hsa05211 Kidney Kidney 
GSE15471 19260470 Pancreatic Cancer hsa05212 Pancreas Pancreas 
GSE16515 19732725 Pancreatic Cancer hsa05212 Pancreas Pancreas 
GSE19728 
 
Glioma hsa05214 Brain Cerebral cortex 
GSE21354 
 
Glioma hsa05214 Brain, Spine Cerebral cortex 
GSE6956 18245496 Prostate Cancer hsa05215 Prostate Prostate 
GSE6956 18245496 Prostate Cancer hsa05215 Prostate Prostate 
GSE3467 16365291 Thyroid Cancer hsa05216 Thyroid Thyroid gland 
GSE3678 
 
Thyroid Cancer hsa05216 Thyroid Thyroid gland 
GSE18842 20878980 Non-Small Cell Lung 
Cancer 
hsa05223 Lung Lung 
GSE19188 20421987 Non-Small Cell Lung 
Cancer 
hsa05223 Lung Lung 
GSE3585 17045896 Dilated 
cardiomyopathy 
hsa05414 Heart Heart muscle 
The inputs for both MAGNETO and ORA were lists of increased length (10, 50, 100, 200) of 
differentially expressed genes. The pipeline employed to calculate the differentially expressed genes 
was the same used by Tarca et al. 2012. Briefly, the datasets were normalized using the RMA 
algorithm (Irizarry et al. 2003) available with the affy package (Gautier et al. 2004) of Bioconductor 
(Gentleman et al. 2004). The differential expression between the two sample groups was computed 
using the limma package (Smyth 2004). The differently expressed genes were selected if the false 
discovery rate was less than 0.1 and then upregulated genes were ranked according to their log fold 
change. 
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The results section is divided into three main subsections. In the first subsection, we present 
ATtRACT a database collecting the RBPs and associated binding sites. In the second subsection, we 
present the results regarding the analyses and the regulation of alternative splicing in the pig 
infarcted myocardium. In the third subsection, we present the results obtained with MAGNETO. 
 
ATtRACT 
ATtRACT interface 
ATtRACT integrates a user-friendly interface. The interface allows the users to access to six main 
sections (Fig 17). The first section allows querying the database. The second allows the searches for 
a specific motif. The third allows scanning one or more RNA sequences searching for RBP binding 
sites. The fourth allows discovering enriched motifs in a set of related sequences and comparing 
them with the motifs present in ATtRACT. The fifth allows downloading part of or the entire 
database. The sixth allows to access to the statistics of the database. Each element of the interface 
is associated with images, tooltips, and simple explanations to facilitate user experience and 
usability. 
ATtRACT content 
ATtRACT contains information on 370 hand-curated and experimentally validated RBPs associated 
with 1583 consensus motifs out of which 192 were not present in any other database and they 
account for the 15% of the total content of ATtRACT database.  
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Table 6 shows the percentage of the experimentally validated motifs extracted from each database 
included in ATtRACT and in parenthesis the percentage that they represent.  
Note that the table takes into consideration the binding specificity of the RBP, the experiments, and 
the organisms, meaning that a motif is considered a distinct entry if: (i) it binds to a different RBP or 
(ii) it was identified with a different experimental approach or (iii) it was identified in a different 
Figure 17: Home page and user interface of ATtRACT. The page is divided into 6 main sections. The first section allows querying the 
database. The second searches for a specific motif. The third scans one or more RNA sequences searching for RBP binding sites. The 
fourth allows discovering enriched motifs in a set of related sequences and comparing them with the motifs present in ATtRACT. The 
fifth allows downloading part of or the entire database. The sixth permits to have access to the statistics of the database. 
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organism. E.g. the motif “ACGCGCC” is considered as two distinct entries because it binds either 
SRSF1 or RBM8A.  
Table 6: Total and percentage of experimentally validated consensus motifs extracted from each database. The first row represents 
the number of motifs from each database included in ATtRACT and the percentage (in parenthesis) that they represent. The second 
row represents the number of unique motifs, i.e. motifs that are not present in the remaining database. Note that ATtRACT might 
contain redundant motifs if they were defined based on different methods. From that the discrepancy between the total number of 
motifs (1583) and those unique (1434). 
Database CISBP-RNA RBPDB SpliceAid-F AEDB PDB 
Number of consensus motifs 312 
 (19.7%) 
226 
(14.3%) 
775 (48.9%) 95 
(6.0%) 
256 (16.2%) 
Unique motifs 229 
(17.9%) 
120 
(9.4%) 
659 (51.5%) 79 
(6.2%) 
192 
(15.0%) 
ATtRACT statistics 
ATtRACT contains only motifs whose length varies from 4 to 12 nucleotides. The motifs of 7 
nucleotides long are the most represented (Fig 18). 
 
Figure 18: The graph represents the distribution of motifs in ATtRACT. The motifs of 7 nucleotides long are the most represented. 
In total, ATtRACT contains motifs from 38 different eukaryotic organisms (Fig 19). The most 
represented organism, in terms of motifs, is Homo sapiens with 67.2% of the total motifs. Drosophila 
melanogaster follows with 10.5% of the total motifs. 
The most representative experiments in ATtRACT are the SELEX and the UV cross-linking (Fig 20).  
Notice that this statistic takes into account only the experiment and not the motifs that are 
generated by the experiments. 
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Figure 19: The pie chart represents distribution of organisms in ATtRACT. The human motifs are the most represented with the 67.2% 
of the whole database 
 
 
 
Figure 20: The pie chart represents the distribution of motifs by experimental approach in ATtRACT. The SELEX experiments and the 
UV cross-linking are the most represented. 
The most represented domains are the RRM and the KH. They account for more than the 70% of all 
the domains in ATtRACT (Fig 21). 
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Search for RBPs 
Users can interrogate ATtRACT through a broad range of different queries. Users can search 
information about specific entries of the database simply by typing or choosing one or a 
combination of the following options: Official Gene name (i.e.: "SRSF4"), Synonyms (i.e. "SFRS4") 
Gene ID (i.e. "ENSG00000136450"), Minimum or maximum length of motifs, Type of experiments, 
Organisms and/or Domains. Search criteria can be combined by using combinations of queries. The 
results are displayed in tabular format (Fig 22). The file, containing the search results, can be 
downloaded by clicking on the drop-down menu on the top of the page. Two different file formats 
are available for download: the commas and the tab separated value. The users can further search 
the entries of the table through a whole text search using the search box. It is also possible to print 
or copy the results to the clipboard. The tables are sortable simply by clicking on the arrows in the 
header of the table. The following fields are displayed on the table: gene name, gene identifier, 
organism, binding sites, PubMed identifier, type of experiment, domain, gene ontology, the 
sequence logo and quality score. One of the main characteristics of ATtRACT is the integration with 
the GO database; by clicking the corresponding button in the go terms column, users can investigate 
the GO terms associated to RBPs. A modal window will show the cellular components, the molecular 
functions and the biological processes associated to the RBP. 
Figure 21: The pie chart represents the domains distribution available in ATtRACT. The RRM and the KH domains are the most 
represented. 
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Figure 22: The typical output of ATtRACT database. The columns represent in order: the gene name, the gene identifier, the organism, 
the motif, the length of the motif, the PubMed identifier, the experiment, the domain(s), the GO terms, the logo and the Qscore. 
A hyperlink is available in the cell table corresponding to the gene name and the gene id.  The 
browser redirects to the UniProt database if the gene name is clicked, otherwise, the browser 
redirects to the page associated with the Ensembl database if the gene identifier is clicked. In few 
cases, the redirection, due to the lack of annotation, occurs through other repositories. Moreover, 
when the experiment is NMR or X-ray we have added a hyperlink to the corresponding PDB entry in 
the column experiment. Finally clicking on motif logo is possible to download the position-specific 
probability matrix (PPM). 
Search for a specific motif 
Users can search for specific motifs by submitting a sequence ranging from 4 to 12 nucleotides. The 
search module supports IUPAC ambiguous notation. By default, the search module retrieves any 
motif that contains the sequence in the input. A perfect match search is executed if the motif is 
enclosed between quotes. The results are displayed as a table and are available for download. The 
same fields mentioned in the previous paragraph (see Search for RBPs paragraph and Fig 22) are 
displayed. 
Scan sequence interface 
In ATtRACT, the BWT algorithm is implemented to scan the sequences. Users can upload a file 
containing one or more RNA/DNA sequences in fasta or multi-fasta format and scan the file 
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searching for the presence of motifs. The user can restrict the search by selecting a specific organism 
and/or motifs of a certain length. The results are provided in tabular format (Fig 23) and are 
downloadable. With respect to the search RBPs and motifs modules, four more fields are added to 
the headers of the results tables: (i) the offset (ii) Exon250, (iii) CDS, (iv) intron (please refer to the 
Materials and Methods section). The offset represents the distance in terms of nucleotides at which 
it is possible to locate the motif, starting from the beginning of the sequence. In order to better 
visualize the results, a plot is provided by ATtRACT for each scanned sequence. The x-axis represents 
the sequence length; each bin represents a nucleotide of the input sequence. The number of motifs 
is represented in the y-axis. Each point in the graph represents the starting position of a motif across 
the input sequence. The higher the dot is on the y-axis, the more motifs start in that position. A red-
yellow color scale distinguishes the dots. The redder the dots are, the higher the concentration of 
motifs is. It is possible to zoom-in the graph with the mouse wheel and interact with it by clicking 
on the dots. A table will show all RBPs, the motifs and the organisms associated with that position. 
MEME and Tomtom Interface 
ATtRACT integrated a pipeline for de novo motif discovery. Users can upload:  
 a set of sequences in multi-fasta format (3000 nucleotides maximum). MEME will analyze 
the sequences to find the de novo motifs 
 the output of a de novo motif analysis done through MEME/MEMERIS (Hiller et al. 2006) 
 a position weight matrix (PWM) representing the results of other de novo motifs finder such 
as DRIMust (Leibovich et al. 2013), XXmotifs (Luehr et al. 2012) or cERMIT (Georgiev et al. 
2010).  
Tomtom is integrated to find those de novo motifs that look like the ones present in ATtRACT. If a 
multi-fasta file is submitted, other parameters must be taken into consideration. 
 
74 
 
 
Figure 23: Example of the results page displaying the sequence scan output. On the top of the page the results appear in tabular 
format. The bottom of the page displays the graph showing the frequency and position of motifs in the input sequence 
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Figure 24: The typical output of de novo motif analysis. A) De novo motifs discovered by MEME. B) Tomtom Output. C) Enriched 
motifs discovered by MEME. D) Brief summary of the characteristics of the RBPs that bind the motif. E) Alignment between the motifs 
available in ATtRACT and the ones discovered by meme. 
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The motifs distribution indicates how the occurrences of motifs are distributed along the 
sequences. Users can choose between three possibilities: 
 one motif per sequence (oops model) 
 zero or one motif per sequence (zoops model) 
 any number of repetitions (anr model) (for further information visit: 
http://meme.nbcr.net/meme/meme-input.html). 
The field named E-value represents the significance threshold for both MEME and Tomtom. Since 
the E-value is influenced by the dimension of the searching dataset, users can also extract a subset 
of the ATtRACT database in order to improve the E-Value. For example, it is possible to choose as a 
search space all the motifs associated to a particular organism or of a particular length, or a 
combination of both. 
The results page (Fig 24) is divided into two sections: at the top of the page, the de novo motifs, 
discovered by MEME/MEMERIS or uploaded by the users through a PWM, are shown, then in the 
next section the significant matches discovered by Tomtom are displayed. The Tomtom results 
section is further subdivided into three columns: the de novo motifs are represented in the first 
column; a brief summary of the characteristics of the RBPs is shown in the second column; an 
alignment figure between the motif present in the ATtRACT database and the de novo motif is 
shown in the third column. Both the results of MEME analysis (if performed through our database) 
and the significant matches discovered by Tomtom are downloadable. 
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Analysis and regulation of alternative splicing in the pig infarcted 
myocardium 
Analysis of isoform switching 
In order to investigate the changes in alternative splicing after MI, we collected the RNAs of 4 
different heart cell types – cardiomyocytes, fibroblasts, endothelial cells and macrophages (CMs, 
FBs, ECs and MFs) – at 3 different time points (day 0 no infarct, 3 days post MI and 7 days post MI). 
Transcript abundance was estimated with RSEM by aligning the reads with the pig reference 
transcriptome.  
The aim of our work was to find the genes that showed an isoform switching, meaning transcript 
pairs that were negatively correlated in terms of expression in two different time points (please see 
materials and methods section for details). In the pig, 25322 genes are annotated. A little bit more 
than a half (Fig 25 green bars) were expressed more than 1 TPM in all the cell types and time points. 
An exception was represented by the CMs at day 0 for which only one-third of the annotated genes 
were expressed more than 1 TPM.  On average, 87.2% of the genes expressed a single isoform and 
more than 1 TPM in each condition, the remaining 12.8% expressed more than one transcript (Fig 
25 blue bars).  
Globally, we detected 210 genes undergoing an isoform switching in all the cell types and time 
contrasts, representing only a small part of the potential isoform switching events. Fig 26 shows the 
quantification of alternatively spliced genes for all the cell types and time points. Alternatively 
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spliced genes are almost equally distributed among all the cell types, in this respect a prevalence of 
genes undergoing isoform switch is observed in the endothelial cells with respect to the other cell 
types. With respect to the time contrast, an increased number of alternatively spliced genes was 
observed in the day0 vs day7.  
 
Figure 26: The number of genes undergoing isoform switching in each cell type and time contrast is shown. The numbers on the top 
of each bar represent the number of genes for which an isoform switch is detected. Each colour represents a different time contrast. 
Alternatively spliced genes are almost equally distributed among all cell types with a little prevalence of ECs with respect to the other 
cell types. 
Isoform switches in Cardiomyocytes  
Globally, 56 unique genes undergoing an isoform switch were identified in CMs in each time contrast 
(Table 7). For 13 of them (highlighted in red), at least one protein, expressed by the alternatively 
spliced gene, was detected at the proteomic level in the time contrast. 
Table 7: The genes undergoing isoform switch are shown. In total, 56 distinct genes are detected, for 13 of them (highlighted in red) 
at least a protein is detected at the proteomic level in the time contrast.  
Gene 3v0 7v0 7v3 description 
ABCA6 
 
X 
 
ATP binding cassette subfamily A member 6 
ACTN3 
  
X actinin, alpha 3 
APOD X 
  
Apolipoprotein D 
APOO 
 
X 
 
Apolipoprotein O 
ASCC1 
 
X 
 
Sus scrofa activating signal cointegrator 1 complex subunit 1 (ASCC1). 
BTK 
 
X X Tyrosine-protein kinase BTK 
C1orf27 
  
X chromosome 1 open reading frame 27 
CD86 X 
 
X Sus scrofa CD86 molecule (CD86), mRNA. 
CISD3 
 
X 
 
CDGSH iron sulfur domain 3 
CMPK2 X 
  
cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial 
COMTD1 
  
X catechol-O-methyltransferase domain containing 1 
DIS3L 
  
X DIS3 like eXsome 3'-5' eXribonuclease 
28 27
41
37
35
32
46
48
17
24
43
34
Cardiomyocytes Fibroblasts Endothelial cells Macrophages
Number of genes undergoing isoform switches per cell type
3 vs 0 7 vs 0 7 vs 3
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EXC1 X X 
 
eXcyst complex component 1 
FCGR1A 
 
X 
 
High affinity immunoglobulin gamma Fc receptor I 
FHOD3 
  
X formin homology 2 domain containing 3 
GGT1 
 
X 
 
Sus scrofa gamma-glutamyltransferase 1 (GGT1), mRNA. 
HAGHL X X 
 
hydroxyacylglutathione hydrolase-like 
HCFC1R1 
 
X 
 
host cell factor C1 regulator 1 (XPO1 dependent) 
IFT52 X X 
 
intraflagellar transport 52 
IL17D X 
  
interleukin 17D 
KDELC1 X X 
 
KDEL (Lys-Asp-Glu-Leu) containing 1 
KIAA1549 
  
X KIAA1549 
LARS X X 
 
leucyl-tRNA synthetase 
LPIN3 X X 
 
lipin 3 
LRPPRC X X 
 
leucine rich pentatricopeptide repeat containing 
LYRM7 
  
X LYR motif containing 7 
METTL1 
  
X methyltransferase like 1 
MTFMT X X 
 
mitochondrial methionyl-tRNA formyltransferase 
NDUFAF7 X X 
 
NADH dehydrogenase (ubiquinone) complex I, assembly factor 7 
NELFE X X 
 
negative elongation factor complex member E 
NIPAL4 
  
X NIPA-like domain containing 4 
NIT1 X X 
 
nitrilase 1 
OSBPL3 X 
 
X oxysterol binding protein-like 3 
PGF X X 
 
Placenta growth factor 
PLA2G6 
 
X 
 
phospholipase A2, group VI (cytosolic, calcium-independent) 
POLR1E X X 
 
polymerase (RNA) I polypeptide E, 53kDa 
PTRH1 
 
X 
 
peptidyl-tRNA hydrolase 1 homolog 
RALGAPB X X 
 
Ral GTPase activating protein, beta subunit 
RCCD1 X 
  
RCC1 domain containing 1 
S100A14 
  
X S100 calcium binding protein A14 
SEMA7A X X 
 
semaphorin 7A, GPI membrane anchor (John Milton Hagen blXd group) 
STAT5A X X 
 
Signal transducer and activator of transcription 5A 
TBC1D31 
  
X TBC1 domain family, member 31 
TEX264 
 
X 
 
testis expressed 264 
TM4SF18 X X 
 
transmembrane 4 L six family member 18 
TN-X 
 
X X Sus scrofa tenascin-X (TN-X), mRNA. 
TNFRSF17 X 
  
tumor necrosis factor receptor superfamily, member 17 
TNRC6C 
 
X 
 
trinucleotide repeat containing 6C 
TRIM44 X X 
 
tripartite motif containing 44 
TRIM52 
  
X tripartite motif containing 52 
UBXN2A X 
  
UBX domain protein 2A 
UXT 
 
X 
 
Protein UXT 
ZAP70 X X 
 
zeta-chain (TCR) associated protein kinase 70kDa 
ZNF212 
 
X 
 
zinc finger protein 212 
ZNF316 X X 
 
zinc finger protein 316 
 For each time contrast, we performed an ORA using the human annotation. All the pig genes 
orthologues one to one to the human were retrieved and used as testing set. Few GO terms were 
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overrepresented in CMs (Table 8, Table 9, Table 10) reflecting the fact that alternatively spliced 
genes do not participate in a global process but take part in distinct processes.  
Table 8: Enriched GO terms for CM at day 3 vs day 0.  
CM3v0 domain description genes involved 
GO:0045086 BP positive regulation of interleukin-2 biosynthetic process CD86, STAT5A 
 
Table 9: Enriched GO terms for CM at day 7 vs day 0 
CM7v0 domain description genes involved 
GO:0047497 BP mitochondrion transport along microtubule LRPPRC, UXT 
GO:0045579 BP positive regulation of B cell differentiation STAT5A, BTK 
 
Table 10: Enriched GO terms for CM at day 7 vs day 3 
CM7v3 domain description genes involved 
GO:0042113 BP B cell activation BTK, CD86 
GO:0008176 MFu tRNA (guanine-N7-)-methyltransferase activity METTL1 
GO:0043527 CC tRNA methyltransferase complex METTL1 
 
Isoform switches in Fibroblasts 
In FBs, 53 distinct genes undergoing isoform switching were identified in each time contrast (Table 
11). For 16 of them (highlighted in red) at least one protein, expressed by the alternatively spliced 
gene, is detected at the proteomic level in the time contrast.  
Table 11: The genes undergoing isoform switching in FBs are shown. In total, 56 distinct genes were detected, for 16 of them 
(highlighted in red) at least one protein is detected in the time point. 
Gene 3v0 7v0 7v3 description 
ACVR2B 
  
X Sus scrofa activin A receptor, type IIB (ACVR2B), mRNA. 
ADAMTS12  X 
 
ADAM metallopeptidase with thrombospondin type 1 motif, 12 
AKIP1 
 
X X A-kinase interacting protein 1 
ANKRD6 
 
X 
 
ankyrin repeat domain 6 
ATAT1 X 
  
Sus scrofa alpha tubulin acetyltransferase 1 (ATAT1), mRNA. 
BEST1 X X 
 
bestrophin 1 
C7H6orf12 
 
X X Uncharacterized protein 
CCNI2 X 
 
X cyclin I family, member 2 
CD46 X X 
 
CD46 molecule, complement regulatory protein 
CD83 
 
X 
 
CD83 molecule 
CHM X 
 
X choroideremia (Rab escort protein 1) 
CISD3 
 
X 
 
CDGSH iron sulfur domain 3 
CTLA4 
  
X Sus scrofa cytotoxic T-lymphocyte-associated protein 4 (CTLA4), mRNA. 
CU463271  X 
 
Not Available 
DMXL1 X X 
 
Dmx-like 1 
ELP6 
 
X X elongator acetyltransferase complex subunit 6 
EVI5 
 
X X ecotropic viral integration site 5 
FANCE X X 
 
Fanconi anemia group E protein 
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FASTKD1 X X 
 
FAST kinase domains 1 
FBX6 X X 
 
F-box protein 6 
GGT1 X X 
 
Sus scrofa gamma-glutamyltransferase 1 (GGT1), mRNA. 
GK X 
  
glycerol kinase 
GPR34 X 
  
G protein-coupled receptor 34 
HXK2 
 
X X hXk microtubule-tethering protein 2 
HSD17B12 
 
X 
 
hydroxysteroid 17-beta dehydrogenase 12 
IGF2BP2 X 
  
insulin-like growth factor 2 mRNA binding protein 2 
JCHAIN X 
 
X joining chain of multimeric IgA and IgM 
KIAA1549 X X 
 
KIAA1549 
MAST4 X X 
 
microtubule associated serine/threonine kinase family member 4 
METTL1 X X 
 
methyltransferase like 1 
MTFMT 
 
X X mitochondrial methionyl-tRNA formyltransferase 
NDUFAF7 X X 
 
NADH dehydrogenase (ubiquinone) complex I, assembly factor 7 
NNAT X 
  
Sus scrofa neuronatin (NNAT), mRNA. 
OSBPL3 
  
X oxysterol binding protein-like 3 
PDZD2 X 
  
PDZ domain containing 2 
PNPLA4 X 
 
X patatin-like phospholipase domain containing 4 
RECQL4 
  
X RecQ protein-like 4 
SCML2 X 
  
sex comb on midleg-like 2 (Drosophila) 
SLC25A14 
 
X 
 
Brain mitochondrial carrier protein 1 
SORCS1 
 
X 
 
sortilin-related VPS10 domain containing receptor 1 
STXBP4 
  
X syntaxin binding protein 4 
TBC1D31 X 
 
X TBC1 domain family, member 31 
TFRC X X 
 
Sus scrofa transferrin receptor (p90, CD71) (TFRC), mRNA. 
THSD7A X 
 
X thrombospondin type 1 domain containing 7A 
TSHR 
 
X X Sus scrofa thyroid stimulating hormone receptor (TSHR), mRNA. 
TTC21A 
 
X X tetratricopeptide repeat domain 21A 
UMPS 
 
X X uridine monophosphate synthetase 
UPF3B 
 
X 
 
UPF3 regulator of nonsense transcripts homolog B (yeast) 
VWF X 
 
X Sus scrofa von Willebrand factor (VWF), mRNA. 
ZBTB3 
 
X X zinc finger and BTB domain containing 3 
ZFYVE28 X 
  
zinc finger, FYVE domain containing 28 
ZNF77 
 
X X zinc finger protein 77 
ZNFX1 
  
X NFX1-type zinc finger-containing protein 1 
 
Interestingly, 11 genes (Table 12) showed a non-significant difference (<10TPM) at the gene 
expression level between two time points showing that alternative splicing provides additional 
genetic complexity that is not reflected by total gene expression levels. 
Table 12: Genes showing a difference in expression less than 10 TPM between the selected time points 
Time contrast Gene names 
FB 7v3 CCNI2, C7H6orf12, MTFMT, PNPLA4, ACVR2B 
FB 7v0 CU463271.1, BEST1, CD46, FBXO6, FANCE, NDUFAF7 
FB 3v0 FANCE 
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Also in the case of FBs, few overrepresented GO terms were found (Table 13 and Table 14).  
Table 13: Enriched GO terms for FBs at day 3 vs day 0 
FB3v0 Domain Description Genes involved 
GO:0001948 MFu glycoprotein binding TFRC, VWF, FBXO6* 
 
Table 14: Enriched GO terms for FBs at day 7 vs day 3 
FB7v3 domain description genes involved 
GO:0071756 CC pentameric IgM immunoglobulin complex JCHAIN 
GO:0071750 CC dimeric IgA immunoglobulin complex JCHAIN 
 
Isoform switches in Endothelial cells 
In ECs, 86 distinct genes undergoing isoform switching were identified in each time contrast (Table 
15). For 16 of them (highlighted in red) at least one protein, expressed by the alternatively spliced 
gene, is detected at the proteomic level in the time contrast. 
Table 15: The genes undergoing isoform switching in ECs are shown. In total, 86 distinct genes are detected, for 16 of them 
(highlighted in red) at least one of transcript is detected at the proteomic level in the time contrast. 
Gene 3v0 7v0 7v3 description 
ABHD12B 
  
X abhydrolase domain containing 12B 
ADAMTS12 X 
 
X ADAM metallopeptidase with thrombospondin type 1 motif, 12 
AKAP17A X 
  
A-kinase anchor protein 17A 
ANKRD6 
 
X 
 
ankyrin repeat domain 6 
ANKS6 
 
X X ankyrin repeat and sterile alpha motif domain containing 6 
ATAT1 X X 
 
Sus scrofa alpha tubulin acetyltransferase 1 (ATAT1), mRNA. 
ATG5 
  
X autophagy protein 5 
BTK X 
 
X Tyrosine-protein kinase BTK 
C1orf27 
 
X 
 
chromosome 1 open reading frame 27 
C7H6orf12 
 
X 
 
Uncharacterized protein 
CARMIL2 
 
X 
 
Capping protein, Arp2/3 and myosin-I linker protein 2 
CC2D1B 
  
X coiled-coil and C2 domain containing 1B 
CDH2 X 
 
X cadherin 2, type 1, N-cadherin (neuronal) 
CEACAM16 X 
  
carcinoembryonic antigen-related cell adhesion molecule 16 
CH242-
204P3.6 
X 
  
Not available 
CH242-
486P11.2 
 X 
 
Uncharacterized protein 
CLEC5A X 
  
C-type lectin domain family 5 member A 
COQ10A 
 
X 
 
coenzyme Q10A 
CSF3 X 
 
X Sus scrofa colony stimulating factor 3 (granulocyte) (CSF3), mRNA. 
DCAF17 X X 
 
DDB1 and CUL4 associated factor 17 
DCLRE1A 
 
X X DNA cross-link repair 1A 
DHX29 
 
X 
 
DEAH (Asp-Glu-Ala-His) box polypeptide 29 
DMXL1 X X 
 
Dmx-like 1 
DNTT 
 
X 
 
DNA nucleotidyleXtransferase 
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DPPA2 
 
X 
 
developmental pluripotency associated 2 
EGFLAM 
  
X EGF like, fibronectin type III and laminin G domains 
ENPP3 X X 
 
Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 
FASTKD1 X X 
 
FAST kinase domains 1 
FCER1A X X 
 
Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide 
FST 
  
X Sus scrofa follistatin (FST), mRNA. 
GK X 
  
glycerol kinase 
GNB5 X 
 
X guanine nucleotide binding protein (G protein), beta 5 
GPCPD1 X X 
 
glycerophosphocholine phosphodiesterase 1 
HAGHL 
 
X 
 
hydroxyacylglutathione hydrolase-like 
HDAC10 X 
 
X histone deacetylase 10 
HP 
 
X 
 
Sus scrofa haptoglobin (HP), mRNA. 
ICE2 X 
 
X interactor of little elongation complex ELL subunit 2 
IFT81 X 
  
intraflagellar transport 81 
KANSL1L 
  
X KAT8 regulatory NSL complex subunit 1-like 
KIAA1549 X 
  
KIAA1549 
LINS 
 
X 
 
lines homolog (Drosophila) 
LMLN 
 
X X leishmanolysin-like (metallopeptidase M8 family) 
LONRF3 X 
  
LON peptidase N-terminal domain and ring finger 3 
LRRC36 
  
X leucine rich repeat containing 36 
LYRM7 X X 
 
LYR motif containing 7 
MAGIX 
 
X 
 
MAGI family member, X-linked 
METTL1 
 
X 
 
methyltransferase like 1 
MME X X 
 
Neprilysin 
MST1R X 
 
X macrophage stimulating 1 receptor 
MTCP1 
  
X mature T-cell proliferation 1 
MTFMT X 
 
X mitochondrial methionyl-tRNA formyltransferase 
MYH7 
 
X X Sus scrofa myosin, heavy chain 7, cardiac muscle, beta (MYH7), mRNA. 
NCAM1 X X 
 
neural cell adhesion molecule 1 
NCOA1 X 
  
Sus scrofa nuclear receptor coactivator 1 (NCOA1), mRNA. 
NNAT 
 
X X Sus scrofa neuronatin (NNAT), mRNA. 
NOA1 
 
X X nitric oxide associated 1 
NPHP1 
 
X X nephronophthisis 1 (juvenile) 
NR6A1 X 
  
Nuclear receptor subfamily 6 group A member 1 
OMA1 X 
 
X OMA1 zinc metallopeptidase 
OSBPL3 X 
  
oxysterol binding protein-like 3 
OVCA2 X 
 
X ovarian tumor suppressor candidate 2 
PDZD11 
 
X 
 
Sus scrofa PDZ domain containing 11 (PDZD11), mRNA. 
POFUT1 
 
X X protein O-fucosyltransferase 1 
POLR1E X 
 
X polymerase (RNA) I polypeptide E, 53kDa 
PTGS2 X 
  
Prostaglandin G/H synthase 2 
RCCD1 X 
 
X RCC1 domain containing 1 
REPS2 
 
X 
 
RALBP1 associated Eps domain containing 2 
RHBDL1 
 
X X rhomboid, veinlet-like 1 (Drosophila) 
S100A9 
 
X X Sus scrofa S100 calcium binding protein A9 (S100A9), mRNA. 
S100PBP X 
 
X S100P binding protein 
SGCA 
 
X 
 
Sus scrofa sarcoglycan, alpha (50kDa dystrophin-associated glycoprotein) 
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SLA-DRB5 
  
X Not available 
SLBP* X 
  
stem-lXp binding protein 
SLC25A14 X 
  
Brain mitochondrial carrier protein 1 
SLC35B1 
 
X X solute carrier family 35 member B1 
SMPDL3A 
 
X 
 
Acid sphingomyelinase-like phosphodiesterase 3a 
SNX21 
 
X X sorting nexin family member 21 
TCAIM X 
 
X T cell activation inhibitor, mitochondrial 
THSD7A 
 
X X thrombospondin type 1 domain containing 7A 
TN-X 
 
X X Sus scrofa tenascin-X (TN-X), mRNA. 
UMPS X 
 
X uridine monophosphate synthetase 
ZBTB3 
 
X X zinc finger and BTB domain containing 3 
ZCCHC18 X X 
 
zinc finger, CCHC domain containing 18 
ZFYVE16 
 
X X zinc finger, FYVE domain containing 16 
ZMIZ1 
 
X X zinc finger, MIZ-type containing 1 
ZNF212 
  
X zinc finger protein 212 
Also in ECs, eight genes (Table 16) showed a non-significant difference (<10TPM) at the gene 
expression level between two time points. 
Table 16: Genes showing a difference in expression less than 10 TPM between the selected time points 
Time contrast Gene name 
EC 7v3 OMA1, ATG5, CC2D1B, LMLN, KANSL1L 
EC7v0 PDZD11 
EC3v0 ENPP3, CLEC5A 
Few enriched GO terms were found through functional enrichment analysis (Table 17 and Table 18).  
Table 17: Enriched GO terms for ECs at day 3 vs day 0 
EC3v0 Domain Description Genes involved 
GO:0019899 MFu enzyme binding CDH2, HDAC10, NCOA1, CSF3, NR6A1, MST1R 
 
Table 18: Enriched GO terms for ECs at day 7 vs day 0 
EC7v0 Domain Description Genes involved 
GO:0005911 CC cell-cell junction CARMIL2, PDZD11, NPHP1, NCAM1, SGCA 
 
Isoform switches in Macrophages 
In MFs, 79 distinct genes undergoing isoform switching were identified in each time contrast (Table 
19). For 19 of them (highlighted in red) at least one protein, expressed by the alternatively spliced 
gene, is detected at the proteomic level in the time contrast. 
Table 19: The genes undergoing isoform switching in MFs are shown. In total, 79 distinct genes are detected, for 16 of them 
(highlighted in red) at least one protein expressed by the gene is detected at the proteomic level in the time contrast. 
Gene 3v0 7v0 7v3 description 
ADHFE1 X X 
 
alcohol dehydrogenase, iron containing, 1 
AGER 
 
X X Sus scrofa advanced glycosylation end product-specific receptor (AGER) 
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ANO9 
 
X 
 
anoctamin 9 
AP4E1 X 
 
X adaptor-related protein complex 4, epsilon 1 subunit 
APOM X 
  
Apolipoprotein M 
ARG2 X 
  
arginase 2 
BEST1 
 
X 
 
bestrophin 1 
BF 
 
X 
 
Sus scrofa complement factor B (CFB), mRNA. 
BMPER 
 
X 
 
BMP binding endothelial regulator 
C11orf52 
  
X chromosome 11 open reading frame 52 
C15orf41 
 
X 
 
chromosome 15 open reading frame 41 
C15orf52 X 
 
X chromosome 15 open reading frame 52 
CD3D X 
 
X Sus scrofa CD3d molecule, delta (CD3-TCR complex) (CD3D), mRNA. 
COMTD1 X X 
 
catechol-O-methyltransferase domain containing 1 
CU463271  
 
X Not available 
CXCR2 X 
  
chemokine (C-X-C motif) receptor 2 
DCLRE1A 
 
X 
 
DNA cross-link repair 1A 
DHX29 
 
X X DEAH (Asp-Glu-Ala-His) box polypeptide 29 
DZIP1L 
 
X 
 
DAZ interacting zinc finger protein 1-like 
ENSSSCG00 
000001956 
X 
 
X Not available 
FAM122C 
 
X 
 
family with sequence similarity 122C 
FANCE 
 
X 
 
Fanconi anemia group E protein 
FBX6 
 
X 
 
F-box protein 6 
FCER1A X 
 
X Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide 
FCRLB X 
 
X Fc receptor-like B 
FOXM1 
 
X X forkhead box M1 
FOXP3 
 
X 
 
forkhead box P3 
GNB5 X 
 
X guanine nucleotide binding protein (G protein), beta 5 
HSD17B12 X X 
 
hydroxysteroid 17-beta dehydrogenase 12 
ICE2 X 
 
X interactor of little elongation complex ELL subunit 2 
IL17D 
  
X interleukin 17D 
IL17RE 
  
X interleukin 17 receptor E 
KANSL1L X X 
 
KAT8 regulatory NSL complex subunit 1-like 
KCP X 
  
kielin/chordin-like protein 
KIAA2018 
 
X X KIAA2018 
KLRK1 X 
 
X Sus scrofa killer cell lectin-like receptor subfamily K, member 1 (KLRK1) 
LAMA3 
 
X 
 
laminin, alpha 3 
LAYN X X 
 
layilin 
LINS 
 
X 
 
lines homolog (Drosophila) 
LRPPRC X 
 
X leucine rich pentatricopeptide repeat containing 
LYRM7 
 
X X LYR motif containing 7 
MBTPS2 X X 
 
membrane-bound transcription factor peptidase, site 2 
METTL1 X X 
 
methyltransferase like 1 
MIS18BP1 X 
  
MIS18 binding protein 
MTFMT X X 
 
mitochondrial methionyl-tRNA formyltransferase 
MUC1 
 
X 
 
mucin 1, cell surface associated 
MYNN X 
  
myoneurin 
MYOM1 
 
X 
 
myomesin 1 
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NEMF X X 
 
nuclear export mediator factor 
OPHN1 
 
X 
 
Oligophrenin-1 
PHKA1 
  
X phosphorylase kinase, alpha 1 (muscle) 
PIGA 
  
X phosphatidylinositol glycan anchor biosynthesis, class A 
POLR1E 
  
X polymerase (RNA) I polypeptide E, 53kDa 
PRICKLE3 
 
X X prickle homolog 3 
RETN X 
  
Sus scrofa resistin (RETN), mRNA. 
RHBDL1 
 
X X rhomboid, veinlet-like 1 (Drosophila) 
RNASEL 
  
X 2-5A-dependent ribonuclease 
S100A14 X X 
 
S100 calcium binding protein A14 
S100A9 
 
X 
 
Sus scrofa S100 calcium binding protein A9 (S100A9), mRNA. 
S100PBP 
 
X X S100P binding protein 
SLA-DRB5 
 
X X Not available 
SLC25A14 X 
 
X Brain mitochondrial carrier protein 1 
SLC35B4 
 
X X solute carrier family 35 member B4 
SMARCA1 
 
X 
 
SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 1 
SMYD4 X 
 
X SET and MYND domain containing 4 
TCAIM X 
 
X T cell activation inhibitor, mitochondrial 
TEX264 X X 
 
testis expressed 264 
TMEM27 
 
X X Collectrin 
TNFRSF17 X 
  
tumor necrosis factor receptor superfamily, member 17 
TREML-2 
 
X 
 
Trem-like transcript 2 protein 
TSPAN6 X 
 
X Sus scrofa tetraspanin 6 (TSPAN6), mRNA. 
TTC21A 
 
X 
 
tetratricopeptide repeat domain 21A 
TTLL7 
 
X 
 
tubulin tyrosine ligase-like family member 7 
UMPS 
 
X X uridine monophosphate synthetase 
UPF3B X X 
 
UPF3 regulator of nonsense transcripts homolog B (yeast) 
VTN X X 
 
Vitronectin 
ZBTB3 X 
  
zinc finger and BTB domain containing 3 
ZIP4 X X 
 
Zinc transporter ZIP4 
ZNF641 
 
X 
 
zinc finger protein 641 
In MFs, 8 genes (Table 20) showed a non-significant difference (<10TPM) at the gene expression 
level between two time points.  
Table 20: Genes showing a difference in expression less than 10 TPM between the selected time points 
Time contrast Gene name 
MF 7v3 TMEM27 
MF 7v0 ZIP4, S100A14, BEST1, FAM122C, C15orf41, LAYN, TMEM27 
MF 3v0 ZIP4, RETN 
No enriched GO terms were found in MFs. 
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Global analysis of alternatively spliced genes 
To better understand the effect of MI on alternative splicing, we performed further statistical and 
structural analyses. Interestingly, we found that a small group of eight genes were alternatively 
spliced in three cell types without any regards for the time contrasts (Table 21).  
Table 21: The table shows the genes alternative spliced in four cell types. 
Gene name Cell type 
UMPS FB, EC, MF 
ZBTB3 FB, EC, MF 
POLR1E CM, EC, MF 
SLC25A14 FB, EC, MF 
OSBPL3 CM, FB, EC 
KIAA1549 CM, FB, EC 
LYRM7 CM, EC, MF 
The information for the role and localisation of these genes is scarce in general. The KIAA1549 gene 
is localised in the membrane while LYRM7 in the mitochondrion. POLR1E gene and ZBTB3 gene are 
two transcriptional regulators. The UMPS gene encodes for an enzyme that is involved in the de 
novo uridine 5'-monophosphate biosynthesis. The OSBPL3 gene binds to cholesterol and plays a role 
in the regulation of cell adhesion and organisation of the actin cytoskeleton (Lehto et al. 2008). The 
SLC25A14 gene is localised in the mitochondria and is involved in the aerobic respiration.  
Subsequently, we investigated the biotype classification of the alternatively spliced transcripts. 
Based on the transcript biotype annotation available in Ensembl, about 90.2% of transcript isoform 
pairs are potentially translated into proteins (Fig 27). Among the non-coding transcripts, the 
processed transcripts, characterized by the absence of an open reading frame, are predominant in 
EC 3v0, EC 7v0 and FB 7v0 MF 7v3. Nonsense mediated decay transcripts are prevalent mainly in EC 
3v0, MF 7v3, MF 3v0, retained intron transcripts are present mainly in EC 7v3, EC 7v0, and FB 3v0. 
We next investigated the overlap of alternatively spliced genes among the different time contrasts. 
CMs show the biggest overlap (20) between the time contrasts 3v0 and 7v0, while only 2 genes were 
in common between time contrast 3v0 and 7v3 and time contrasts 7v0 and 7v3 (Fig 28a). In other 
cell types, the overlapped genes were more constant.
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Figure 27: Isoform transcript pairs distributions. Each transcript is classified according to the Ensembl transcript biotype. Most of the transcripts are protein coding genes (90.2% on average). Processed 
transcript, nonsense mediated decay and retained intron are also present in a significant percentage 
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In FBs, 12,7, and, 11 genes are shared between time contrasts 3vs0 and 7v0, 3v0 and 7v3, and 7v0 
and 7v3 respectively (Fig 28b). In ECs,11,16, and 17 genes are shared between time contrasts 3vs0 
and 7v0, 3v0 and 7v3, and 7v0 and 7v3 respectively (Fig 28c). In MFs, 14, 14 and 12 genes are shared 
between time contrasts 3v0 and 7v0, 3v0 and 7v3, and 7v0 and 7v3 respectively (Fig 28d). These 
results suggest many of the AS changes observed in the different cell types were maintained over 
time. 
 
Figure 28: The Venn diagram shows the number of alternative spliced genes across different time points. CMs shared the biggest 
overlap (20 genes) among time point 3v0 and 7v0 (A). In other cell types, the genes overlap among time points is more stable (B, 
C,D). 
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According to Kriventseva et al. 2003, alternative splicing tends to insert or delete or alter protein 
domains more frequently than expected by chance.  To investigate the impact of alternative splicing 
at the protein structural level, we investigated the consequences that isoform switching potentially 
had on the gain or loss on the proteins' domains. To characterize the domains annotated in each 
transcript isoform pairs, we employed the information available in the PFAM database (Version 
30.0). Given a transcript switching pair, we defined a domain as inserted if the transcript is 
upregulated, deleted if downregulated. Notice that, in Table 22, the domains that are in common 
between the transcript pairs are not shown even though they can be modified by alternative splicing 
events. Interestingly, alternative splicing of the APOD gene potentially changed the domain by 
inserting a Lipocalin-like domain and by deleting the Triabin domain. Moreover, in the TNFRSF17 
gene, the BCMA, TALL-1 binding domain is inserted in CM3v0 but deleted in MF3v0.  
Table 22: Domains altered by alternative splicing events. The columns represent the gene name, the domain inserted 
or disrupted due to an alternative splicing event and the cell type and time contrast where the domain is being altered.  
gene name Inserted domain Deleted domain Where 
TNFRSF17 BCMA, TALL-1 binding   CM3v0 
APOD Lipocalin-like domain Triabin CM3v0 
HAGHL Metallo-beta-lactamase 
superfamily 
  CM3v0, CM7v0, 
EC7v0 
NELFE RNA recognition motif   CM3v0, CM7v0 
ZAP70   Protein tyrosine kinase 
Protein kinase domain 
CM7v0 
BTK   PH domain 
Variant SH3 domain 
Protein kinase domain 
Protein tyrosine kinase 
BTK motif 
SH3 domain 
CM7v0, CM7v3, 
EC7v3  
IGF2BP2 RNA recognition motif   FB3v0 
TFRC PA domain 
Peptidase family M28 
Transferrin receptor-like 
dimerisation domain 
  FB3v0 
ZNF77   Zinc-finger double-stranded RNA-
binding 
FB3v0, FB7v0 
CTLA4 Immunoglobulin V-set domain   FB7v3 
NCOA1   Helix-loop-helix DNA-binding 
domain 
EC3v0 
LONRF3   Zinc finger, C3HC4 type  EC3v0 
NR6A1 Zinc finger, C4 type    EC3v0 
ENPP3 Type I phosphodiesterase / 
nucleotide pyrophosphatase 
  EC3v0, EC7v0 
CDH2 Cadherin cytoplasmic region 
 
EC3v0, 
EC7v3 
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ATAT1   GNAT acetyltransferase EC3v0, EC7v0 
NPHP1   SH3 domain 
Variant SH3 domain 
EC7v0, EC7v3 
CDH2   Cadherin cytoplasmic region EC7v3 
TNFRSF17   BCMA, TALL-1 binding MF3v0 
ARG2 Arginase family   MF3v0 
PRICKLE3 LIM domain 
PET Domain 
  MF7v0, MF7v3 
MUC1   SEA domain MF7v0 
ANO9   Calcium-activated chloride 
channel 
MF7v0 
AGER Immunoglobulin domain   MF7v0, MF7v3 
ADHFE1   Iron-containing alcohol 
dehydrogenase  
MF7v0 
SMARCA1   SNF2 family N-terminal domain 
DEAD/DEAH box helicase 
Helicase conserved C-terminal 
domain 
HAND 
SLIDE 
Type III restriction enzyme, res 
subunit 
MF7v0 
Regulation of Alternative Splicing 
Regulation of alternative splicing is a complicated process in which regulatory motifs are recognized 
by a splicing factor, a subclass of RBPs, to activate or repress the inclusion of adjacent exons. Our 
aim was to characterize the regulatory motifs and the splicing factors that regulated alternative 
splicing during MI. For this reason, we designed a pipeline composed of the combination of MEME 
and Tomtom (see material and methods for details). To validate our findings, we employed the 
proteomic profile to assess whether: (i) at least one transcript of the pairs was translated into a 
protein, and (ii) the splicing factor was detected at the proteomic level. Fig 29 and Fig 30 show the 
motifs and the splicing factors that potentially regulate alternative splicing in all the cell types. The 
first column shows the regulatory motifs, the second column the gene(s) alternatively spliced and 
the third column the splicing factors, the number in parenthesis indicates the splicing factor 
expression level. A negative number means that the splicing factor is downregulated, and vice versa. 
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Figure 29: Motifs and splicing factors that potentially regulate alternatively spliced genes in CMs and FBs. The first 
column shows the motifs, the second row the gene(s) alternatively spliced and the third the splicing factors, the number 
in parenthesis indicates the protein expression level. 
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Figure 30: Motifs and splicing factors that potentially regulate alternatively spliced genes in ECs and MFs. The first 
column shows the motifs, the second row the gene(s) alternatively spliced and the third the splicing factors, the number 
in parenthesis indicates the protein expression level. 
Comparison between MAGNETO and the standard enrichment analysis 
method 
Once we investigated the role of AS in the pig infarcted myocardium, we wanted to assess whether 
it was possible to gain more insight into the ORA. For this purpose, we developed a new method 
called MAGNETO, which makes use of information obtained from PINs to improve the ORA results 
94 
 
(see materials and methods). To compare in a systematic and unbiased way the effectiveness of 
MAGNETO with respect to the ORA we employed the approach proposed by Tarca et al. 2012.  
 
Figure 31: The box plots represent the -Log(p-value) distribution of the 21 datasets. Both MAGNETO and the standard ORA method 
are shown. The label on the x-axis represents the method (standard and MAGNETO) the number next to the label represents the 
number of proteins submitted. 
We selected 21 datasets of differentially expressed genes from GEO database for which we can 
assess an association between the phenotype under investigation and a target pathway in KEGG. 
 
Figure 32: The box plots represent the ranks distribution of the 21 datasets. Both MAGNETO and the standard ORA are shown. The 
label on the x-axis represents the method (standard or MAGNETO) the number next to the label represents the number of proteins 
submitted. 
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We selected lists of upregulated genes of increased length (10, 50, 100, 200) and submitted to 
MAGNETO and to the standard ORA method. The two methods were compared on the distributions 
of -Log(p-values) and rank.  
The box plots in Fig 31 show the distributions of -Log(p-values) for the 21 datasets of both MAGNETO 
and the standard ORA method. The box plots in Fig 32 show the ranks distribution for the 21 datasets 
for both MAGNETO and the standard ORA method. It is evident that MAGNETO outperforms the 
standard ORA method in terms of p-value and rank distributions when the number of proteins 
submitted is greater than 50.  
Applying MAGNETO to the pig data 
MAGNETO currently uses information from the human protein interaction network. To apply 
MAGNETO to the pig transcriptomic data it was necessary to convert the genes expressed in the pig 
to the one to one human ortholog. This had also the advantage of employing the more detailed 
human annotation at the cost of losing some pig genes that were highly expressed. The ORA was 
performed by selecting the top 50 expressed genes in each cell type and in each time point. We 
selected a p-value threshold equal to 0.001 Bonferroni corrected. The background was represented 
by the genes that have at least an annotation in the BP domain. The protein lists employed for the 
ORA represented the seed nodes for MAGNETO. Additionally, we selected the IntAct network and 
the heart muscle as tissue since MAGNETO requires a tissue in the input. To demonstrate the 
advantage of MAGNETO over the ORA method, we compared the BPs identified by MAGNETO to 
those obtained with the ORA. 
Protein distribution among Coarse Grained Modules 
The first step of the MAGNETO pipeline was to assign proteins to the CGMs. The CGMs are a gross 
grained representation of a top-level pathway, meaning a set of proteins involved in a very general 
biological process (i.e. gene expression, immune system). It is important to notice that proteins can 
be assigned also to different CGMs, for this reason the sum of the assigned proteins to the CGMs is 
greater than 50. Fig 33 shows how the proteins are assigned to the CGMs. The x-axis represents the 
top-level pathways, if the top-level pathway is absent, the proteins were not assigned. The cell types 
are colour coded and each bar of the same colour corresponds to a different and consecutive time 
point (i.e. the first blue bar corresponds to the number of proteins in CM at day 0 assigned to the 
top-level pathway, the second blue bar corresponds to the number of proteins in CM at day 3 
assigned to the top-level pathway as so on).   
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Interestingly, in FBs, about half of the 50 input proteins (yellow bars) are always assigned to 
“extracellular matrix organization” (25 at day 0, 22 at day 3 and 25 at day 7). FBs are the only cell 
type showing a constant behaviour in terms of proteins assigned to the top-level pathways 
regardless of the time points.  
Conversely, in CMs (blue bars), the proteins assigned to the top-level pathway fluctuate more and 
reflect more the impact of the inflammatory phase. A comparison between proteins involved in top-
level pathway in day 0 (no infarct) with respect to 3 days post MI shows a decrease of proteins 
assigned to muscle contraction (10 less) and metabolism (7 less). This decrease is balanced by an 
increase of proteins assigned to signal transduction (10 more), immune system (14 more), 
developmental biology (10 more) and extracellular matrix organization (8 more). In comparison with 
day 3, at day 7, the proteins assigned to muscle contraction show an increase (5 more) while the 
proteins involved in the immune system are clearly decreased (10 less) coming back to the level of 
day 0. The proteins involved in metabolism, signal transduction and developmental biology and 
extracellular matrix remained at the same level of day 3.  
In MFs (green bars), the proteins involved in immune system undergo an increase (6 more) at day 3 
in comparison with day 0 as well as a slight increase (4 more) is observable in proteins involved in 
hemostasis but then come back to the same level of day 0. 
In ECs (red bars), an increase of proteins involved in developmental biology is observed (6 more) in 
day 3 and day 7 with respect to day 0. A slight increase (5 more) of proteins involved in the immune 
system is detected at day 7 in comparison with day 0. 
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Figure 33: How the proteins are assigned to the CGMs. The cell types are colour coded and each consecutive bar correspond to a different and consecutive time point (i.e. the first blue bar 
corresponds to the number of proteins in CMs at day 0 assigned to the top-level pathway, the second blue bar corresponds to the number of proteins in CMs at day 3 assigned to the top-level 
pathway as so on).  
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MAGNETO: final networks 
The network extracted with MAGNETO are highly representative of the interactions that take place 
in the selected tissue. Fig 34 shows how the number of nodes/proteins needed to connect each 
couple of seed nodes in any of the CGM networks. On average, the final networks are composed of 
261.25 nodes/proteins meaning that about 200 nodes/proteins more were required to connect 50 
seed proteins in input. 
 
Figure 34: Number of nodes/proteins needed to connect each couple of seed nodes in any of the CGM networks. 
The nodes/proteins obtained with MAGNETO represent the testing set for the ORA. The background 
was represented by the BPs domain of the Gene Ontology database.  Even though the BPs were 
Bonferroni corrected and a stringent p-value (0.001) was chosen, the list of overrepresented BPs 
was quite large. Visualizing large lists of overrepresented BPs is not a trivial task. The enriched BPs 
detected by MAGNETO and ORA were visualized through a heatmap. The rows show the name of 
the enriched BPs, the columns represent the different time points and method used (i.e. M0 means 
MAGNETO at day 0, S0 means standard at day 0). The squares represent the number of proteins 
involved in the enriched process, a white square represents no enrichment. Each square adopts a 
red-yellow colour code. The redder the square is, the higher the number of proteins involved in that 
BP are.  This type of representation helps to figure out which are the BPs in common between the 
different time points and which one are specific to the cell type at a certain time point. 
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Enriched processes in Cardiomyocytes 
We first analysed the BP terms enriched in the CM gene lists, comparing the performance of 
MAGNETO to that of ORA. Fig 35 shows the BPs detected in CMs only with ORA but not detected 
with MAGNETO. MAGNETO did not detect these BPs because it deals with a bigger testing set, 
therefore, some of the terms may not appear enriched. In CMs, 7 BPs were enriched using the 
standard ORA. Many of the BPs found by ORA are related to heart and muscle contraction.  
 
Figure 35: BPs detected only with the standard ORA but not detected by MAGNETO in CMs 
Fig 36 shows the BPs detected by MAGNETO in CMs and commonly enriched at days 0, 3, and 7. 
MAGNETO detected 16 BPs commonly enriched, five were also detected with the standard ORA but 
not in all the time points. In comparison with ORA, MAGNETO detected BPs involved in immune 
response and inflammation (Fc-epsilon receptor signalling pathway, MAPK cascade, stimulatory C-
type lectin receptor signalling pathway) and mitochondrial respiration (mitochondrial electron 
transport, cytochrome c to oxygen, mitochondrial electron transport, NADH to ubiquinone, 
mitochondrial respiratory chain complex I assembly). Interestingly, the number of proteins involved 
in immune response and inflammation increased at day 3 and remained stable at day 7, while the 
proteins involved in mitochondrial respiration decreased at day 3 and increased again at day 7. 
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Figure 36: BPs detected by MAGNETO and ORA and enriched at day 0, 3 and 7 in CMs 
Fig 37 shows the BPs detected by MAGNETO in CMs and commonly enriched at day 0 and 3. 
MAGNETO detected 5 BPs in CMs commonly enriched between day 0 and 3, none of them was 
detected with the standard ORA. 
 
Figure 37: BPs detected by MAGNETO and commonly enriched at day 0 and 3 in CMs 
Fig 38 shows the BPs detected by MAGNETO in CMs and commonly enriched at days 0 and 7. The 
BPs enriched at time point 0 and 7 showed a very similar profile between MAGNETO and the 
standard ORA. With respect to the standard ORA, MAGNETO additionally detected the BPs ‘positive 
regulation of canonical Wnt signalling pathway’ at time point 0 and 7, and ‘skeletal muscle 
contraction’ at time point 7. 
Fig 39 shows the BPs detected by MAGNETO in CMs and commonly enriched at days 3 and 7. 
MAGNETO detected 22 BPs commonly enriched between day 3 and 7, two of them (extracellular 
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matrix organization and collagen catabolic process) were enriched also with the standard ORA
 
Figure 38: BPs detected by MAGNETO and ORA and commonly enriched at day 0 and 7 in CMs 
In addition, MAGNETO detected BPs involved in immune response and inflammation (I-kappaB 
kinase/NF-kappaB signalling, NIK/NF-kappaB signalling, wound healing, response to muscle stretch, 
stress-activated MAPK cascade, activation of MAPK activity, T cell receptor signalling pathway), 
proliferation and migration (positive regulation of fibroblast proliferation, positive regulation of cell 
proliferation) and apoptosis. 
 
Figure 39: BPs detected by MAGNETO and ORA and commonly enriched at day 3 and 7 in CMs   
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Fig 40 shows the BPs detected by MAGNETO in CMs and commonly enriched at day 0. MAGNETO 
detected 9 BPs enriched at time point 0, four were also enriched with the standard ORA. The 
enriched BP “muscle contraction” was detected only with the standard ORA at day 7. In comparison 
with ORA, MAGNETO detected in addition BPs involved in ATP production typical of the 
mitochondria. 
 
Figure 40: BPs detected by MAGNETO and ORA and enriched at day 0 in CMs  
Fig 41 shows the BPs detected by MAGNETO in CMs and enriched at day 3. MAGNETO detected 19 
BPs enriched at day 3, two of them (movement of cell or subcellular component and response to 
organic substance) were also detected by the standard ORA. In comparison with ORA, the BPs 
detected by MAGNETO at day 3 were related mainly to immune response and phagocytosis (positive 
regulation of NF-kappaB transcription factor activity, Fc-gamma receptor signaling pathway involved 
in phagocytosis). 
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Figure 41: BPs detected by MAGNETO and ORA and enriched at day 3 in CMs  
Fig 42 shows the BPs detected by MAGNETO in CMs and commonly enriched at day 7. MAGNETO 
detected 8 BPs at day 7, none of them was detected with the standard ORA. In comparison with 
ORA, MAGNETO detected BPs involved mainly in cardiac remodelling (blood vessel development, 
positive regulation of epithelial to mesenchymal transition, heart development). 
 
Figure 42: BPs detected by MAGNETO and enriched at day7 in CMs 
Enriched processes in Fibroblasts 
Fig 43 shows the BPs detected in FBs only with ORA but absent in MAGNETO. MAGNETO did not 
detect these BPs because it deals with a bigger testing set, as a consequence some of the terms may 
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not appear enriched. In FBs, 4 BPs were enriched using the standard ORA.
 
Figure 43: BPs detected only with the standard ORA but not detected by MAGNETO in FBs 
Fig 44 shows the BPs detected by MAGNETO in FBs and commonly enriched at days 0, 3, and 7. 
MAGNETO detected 28 BPs commonly enriched in all the time points in FBs, 8 of them were 
detected also with the standard ORA, both methods mainly enriched BPs related to extracellular 
matrix. MAGNETO additionally detected BPs related to immune response and inflammation (MAPK 
cascade, stimulatory C-type lectin receptor signalling pathway, wound healing, Fc-epsilon receptor 
signalling pathway, response to muscle stretch, response to hypoxia). We did not observe a 
fluctuation in terms of proteins assigned to any of the BPs commonly enriched, unlike in CMs. This 
is consistent with the constant behaviour in terms of proteins assigned to the CGMs (please see 
paragraph Protein distribution among Coarse Grained Modules) 
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Figure 44: BPs detected by MAGNETO and ORA and enriched at days 0, 3 and 7 in FBs 
Fig 45 shows the BPs detected by MAGNETO in FBs and commonly enriched at days 0 and 3, days 0 
and 7 and days 3 and 7. MAGNETO detected 2 BPs commonly enriched at day 0 and 3, four BPs were 
commonly enriched at days 0 and 7, of these the “skin development” was detected also with the 
standard ORA and at day 3. MAGNETO detected 6 BPs commonly enriched at days 3 and 7, of these, 
the BP “extracellular fibril organization” was detected with ORA but only at day 7. Interestingly, in 
comparison with ORA, the BPs detected with MAGNETO and commonly enriched were related to 
fibroblast and cell migration and epithelial cell proliferation.  
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Figure 45: BPs detected by MAGNETO and ORA and commonly enriched at days 0 and 3, at days 0 and 7, and at days 3 and 7 in FBs 
Fig 46 shows the BPs detected by MAGNETO and ORA in FBs and enriched at day 0. MAGNETO 
detected 18 BPs enriched only at day 0. The “cellular response to amino acid stimulus” was detected 
also by the standard ORA and at day 3 and day 7. In comparison with ORA, MAGNETO added 
enriched BPs related to immune response, fibroblast proliferation and the tumor necrosis factor 
signalling. 
 
Figure 46: BPs detected by MAGNETO and ORA enriched at day 0 in FBs 
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Fig 47 shows the BPs detected by MAGNETO and ORA in FBs and commonly enriched at day 3. 
MAGNETO detected 5 enriched BPs at day 3. The BP “platelet aggregation” was detected also with 
the standard ORA at the same day. In comparison with ORA, MAGNETO added BPs related to 
immune response (NIK/NF-kappaB signalling) and platelet aggregation. 
 
Figure 47: BPs detected by MAGNETO and ORA and enriched at day 3 in FBs 
Fig 48 shows the BPs detected by MAGNETO in FBs and commonly enriched at day 7. MAGNETO 
detected 16 BPs enriched at day 7, none of them was detected with ORA. The enriched BPs detected 
by MAGNETO, but not with ORA, were mainly related to cell adhesion (cell-matrix adhesion, 
substrate adhesion-dependent cell spreading), proliferation, migration, and signalling (transforming 
growth factor beta receptor signaling pathway, Fc-gamma receptor signaling pathway involved in 
phagocytosis).  
 
Figure 48: BPs detected by MAGNETO and enriched at day 7 in FBs 
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Enriched processes in Endothelial cells 
Fig 49 shows the BPs detected with ORA but not with MAGNETO in ECs. Considering any of the days, 
ORA detected 6 BPs, two of them were related to cell differentiation even though in two different 
days.  
 
Figure 49: BPs detected only with ORA method but not detected by MAGNETO in ECs 
Fig 50 shows the BPs detected by MAGNETO in ECs and commonly enriched at days 0, 3, and 7. 
MAGNETO detected 35 BPs enriched in all the days in ECs, 6 of them were detected also with the 
ORA method, but two of them (cell-cell adhesion and movement of cell or subcellular component) 
were not enriched in all the days. As in all the other cell types, most of the BPs detected with 
MAGNETO in ECs were related to the immune response, additionally MAGNETO detected the BP 
“leukocyte migration”. Moreover, several BPs detected only with MAGNETO are associated to 
signalling (transforming growth factor beta receptor signalling pathway, Fc-epsilon receptor 
signalling pathway). Like in the CMs, with respect to day 0, the proteins involved in several BPs 
(MAPK cascade, Apoptotic process, positive regulation of gene expression, positive regulation of 
transcription, DNA-templated, negative regulation of transcription from RNA polymerase II 
promoter) decreased at day 3 and remained almost constant at day 7. The proteins involved in BPs 
related to immune response (T cell receptor signalling pathway and Fc-epsilon receptor signalling 
pathway) decreased at day 3 and then increased at day 7, reaching almost the same number of day 
0.  
109 
 
 
Figure 50: BPs detected by MAGNETO and ORA and enriched at days 0, 3 and 7 in ECs 
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Fig 51 shows the BPs detected by MAGNETO in ECs and commonly enriched at days 0 and 3. 
MAGNETO detected 8 BPs commonly enriched at days 0 and 3, none of them was detected with 
ORA. Two BPs detected with MAGNETO were related to growth factor (epidermal growth factor 
receptor signalling pathway and cellular response to growth factor stimulus), and two to 
mitochondrial respiration. 
 
Figure 51: BPs detected by MAGNETO commonly enriched at day 0 and 3 in ECs 
Fig 52 shows the BPs detected by MAGNETO and ORA in ECs and commonly enriched at day 0 and 
7. MAGNETO detected 6 BPs commonly enriched at days 0 and 7, the BP “angiogenesis” was 
detected also by the standard ORA and also at day 3.  
 
Figure 52: BPs detected by MAGNETO and ORA commonly enriched at day 0 and 7 in ECs 
Fig 53 shows the BPs detected by MAGNETO in ECs and commonly enriched at day 3 and 7. 
MAGNETO detected 5 BPs commonly enriched at days 3 and 7, the BP “extracellular matrix 
organization” was detected also by the standard ORA at the same days. In comparison with ORA, 
MAGENTO detected two BPs related to cardiac remodelling (heart development and positive 
regulation of fibroblast proliferation). 
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Figure 53: BPs detected by MAGNETO and ORA commonly enriched at day 3 and 7 in ECs 
Fig 54 shows the BPs detected by MAGNETO and ORA in ECs and enriched at day 0. MAGNETO 
detected 24 enriched BPs in ECs at day 0. Of these, only the BP “response to calcium ion” was 
detected with the standard ORA. Additionally, MAGNETO detected BPs related to signalling pathway 
(negative regulation of transforming growth factor beta receptor signaling pathway, JAK-STAT 
cascade involved in growth hormone signaling pathway), and angiogenesis. 
 
Figure 54: BPs detected by MAGNETO and ORA and enriched at day 0 in ECs 
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Fig 55 shows the BPs detected by MAGNETO in ECs and enriched at day 3. MAGNETO detected 12 
enriched BPs in ECs at day 3. Of these, three of them were enriched also with the standard ORA, 
two of them (rRNA processing, collagen catabolic process) were enriched also at day 7. MAGNETO 
additionally detected BPs related to signalling (regulation of tumor necrosis factor-mediated 
signalling pathway, MyD88-dependent toll-like receptor signaling pathway), healing (wound healing 
and blood vessel development) and the collagen catabolic process. 
 
Figure 55: BPs detected by MAGNETO and ORA commonly enriched at day 3 in ECs 
Fig 56 shows the BPs detected by MAGNETO in ECs and commonly enriched at day 7. MAGNETO 
detected 3 BPs enriched in ECs at day 7, none of them were detected by the standard ORA. 
 
Figure 56: BPs detected by MAGNETO and enriched at day 7 in ECs 
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Enriched processes in Macrophages 
Without any regards for the day, ORA detected 8 BPs in MFs. These BPs were not enriched with 
MAGNETO.
 
Figure 57: BPs detected only with the standard ORA but not detected by MAGNETO in MFs 
Fig 58 shows the BPs detected by MAGNETO in MFs and commonly enriched at day 0, 3, and 7. 
MAGNETO detected 30 BPs commonly enriched in all the days in MFs, the standard ORA shared 2 
enriched BPs but one of them (movement of cell or subcellular component) was enriched only at 
day 3. Like in all the other cell types, also in MFs, most of the BPs detected with MAGNETO were 
related to immune response. Most of the proteins involved in BPs related to the immune response 
and apoptosis, (Fc-epsilon receptor signalling pathway, T cell receptor signalling pathway, 
stimulatory C-type lectin receptor signalling pathway, negative regulation of apoptotic process, 
apoptotic process) were increased at day 3 and slightly decreased at day 7.    
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Figure 58: BPs detected by MAGNETO and ORA and enriched at day 0, 3 and 7 in MFs 
Fig 59 shows the BPs detected by MAGNETO in MFs and commonly enriched at day 0 and 3, at day 
0 and 7, and at day 3 and 7. MAGNETO detected 5 BPs commonly enriched at day 0 and 3. Two of 
them were involved in the Wnt signalling pathway, one in the tumor necrosis factor signalling 
pathway. MAGNETO detected 9 BPs commonly enriched between day 0 and 7. MAGNETO detected 
6 BPs commonly enriched at day 3 and 7, of these, the BP “cell-cell adhesion” showed a discrepancy 
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in the number of proteins involved at day 3 with respect to day 7. The BP “translation” was also 
detected but in a different day. 
 
Figure 59: BPs detected by MAGNETO and ORA and commonly enriched at day 0 and 3, day 0 and 7, day 3 and 7 in MFs 
Fig 60 shows the BPs detected by MAGNETO and ORA in MFs and enriched at day 0. MAGNETO 
detected 9 BPs enriched in MFs at day 0, of these only the BP “response to drug” was enriched 
with the standard ORA. Additionally, MAGNETO detected BPs related to cell proliferation and 
migration.  
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Figure 60: BPs detected by MAGNETO and ORA and enriched at day 0 in MFs 
Fig 61 shows the BPs detected by MAGNETO in MFs and commonly enriched at day 3. MAGNETO 
detected 16 BPs enriched in MFs at day 3, none of them was detected with the standard ORA. The 
BPs detected by MAGNETO were mainly involved in the immune response (regulation of tumor 
necrosis factor-mediated signalling pathway, response to lipopolysaccharide, insulin receptor 
signalling pathway) and cell proliferation. 
 
Figure 61: BPs detected by MAGNETO and enriched at day 3 in MFs 
Fig 62 shows the BPs detected by MAGNETO and ORA in MFs and commonly enriched at day 7. 
MAGNETO detected 9 BPs enriched in MFs at day 7, of these only the “collagen catabolic process” 
was commonly enriched with the standard ORA. Two BPs detected by MAGNETO were related to 
the cellular response to growth factor (cellular response to fibroblast growth factor stimulus and 
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cellular response to transforming growth factor beta stimulus) and leukocyte migration.
 
Figure 62: BPs detected by MAGNETO and ORA and enriched at day 7 in MFs 
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Discussion 
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The work presented in this thesis can be divided into three main part. In the first part, we 
characterized the RBPs and the associated motifs by developing ATtRACT. In the second part, we 
detected the AS events after MI and thanks to the data available in ATtRACT we determined the 
splicing factors and the motifs that potentially regulate AS after MI. In the third part, we developed 
MAGNETO that permitted to depict a global picture of the BPs occurring before and after MI in each 
cell type. In this respect, MAGNETO, is an invaluable resource to gain more insight into the molecular 
processes and to discover new ones. 
 
ATtRACT: - A daTabase of RNA binding proteins and AssoCiated moTifs 
RBPs play a fundamental role in almost every cellular process. The complex and orchestrated 
interplay between RBPs and RNA controls and regulates multiple steps of RNA metabolism such as 
alternative splicing, polyadenylation, mRNA export, translation, stability and degradation (Glisovic 
et al. 2008). Knowledge the RBPs specificity and affinity with the associated binding motifs is 
essential to understand the transcriptional, post-transcriptional and the regulatory mechanisms in 
which RBPs are involved. However, the available information on RBPs and their motifs is currently 
limited, incomplete, and sometimes outdated. Despite advances in recent years, the lack of a 
unified, updated, and non-redundant repository that collects the information on RBPs and their 
associated binding sites not only delays the study of RBP function itself but also precludes the study 
of RNA processing, localization, and regulation in a global manner. 
To address this gap, we developed ATtRACT: A database of RNA-binding proteins and associated 
motifs. ATtRACT was developed to be a ‘one-stop shop’ for the researchers that are involved in the 
study of RBPs. 
ATtRACT represents a unique resource containing manually curated and experimentally validated 
RNA binding proteins and their associated motifs. In comparison to other similar databases, 
ATtRACT adds 192 motifs not available in any other database from 110 different RBPs by retrieving 
the information buried in the PDB database. To our knowledge, ATtRACT is the largest and most 
updated collection of experimentally validated RBPs and associated binding sites. For this reason, it 
represents an invaluable resource to improve our understanding of RBP-RNA interactions and how 
they are regulated. 
In comparison with the available databases, only CISBP-RNA includes more motifs than ATtRACT. 
This is because CISBP-RNA includes also motifs inferred by homology. The strategy adopted by 
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CISBP-RNA is to align the RBDs of different species. If two RBDs show a sequence similarity greater 
than 70%, it is likely that they share similar RNA binding sites. In ATtRACT, the inferred motifs are 
not included because only experimentally validated motifs are contained. Furthermore, a sequence 
similarity greater than 70% is not a condition sufficient to determine that the binding site will be 
identical also in other species. For example: RBFOX1 in humans binds to “UGCAUG” while RBFOX1 
in zebrafish binds to “GCAUG”, even if the domains are almost 100% identical (Fig 63). In Auweter 
et al. 2006 the authors claim that: 
1. U1, G2 and C3 are necessary to form a hydrophobic cage around phenylalanine.  
 U1 and C3 form one hydrogen bond 
 The substitution of U1 by either A or C leads to a loss of free binding energy (ΔΔG) of 4.0 and 
4.5 kJ/mol, respectively. 
 
 
Figure 63: Alignment between the RBFOX1 domains in zebrafish (up) and in human (down). Identical and similar amino 
acids are indicated with stars and dots, respectively. The colours represent the residues according to their 
physicochemical properties (Red : Small (small+ hydrophobic (incl.aromatic -Y)), Blue : Acidic, Magenta: Basic - H, Green 
: Hydroxyl + sulfhydryl + amine + G, Grey: Unusual amino/imino acids etc) 
The binding specificity of “UGCAUG” for RBFOX1 in humans is also confirmed by other papers (Wang 
& Burge 2008; Yeo et al. 2007; Castle et al. 2008; Ponthier et al. 2006). For this reason, we decided 
to leave out the inferred binding motifs. 
ATtRACT was designed to be highly integrated with other databases and tools. To integrate other 
domains of knowledge, the other available databases adopt a cross-referencing technique forcing 
the users to traverse from a database to another to get the desired information. In ATtRACT, the 
information and tools are integrated into the database.  For example, the GO database is integrated 
and users can explore the GO terms in which the RBPs are involved in. Additionally, to our 
knowledge, an RBP database integrating a tool to identify de novo motifs in a set of sequences was 
not available. The users were obliged to upload their files from one application to another. 
Moreover, to our knowledge, in Tomtom, the only available dataset of motifs is derived from CISBP-
RNA, which we believe is not sufficient alone to capture the variability of RNA binding sites (please 
see Table 6). 
123 
 
ATtRACT was also designed to be highly standardized. In this respect, the inconsistency in 
nomenclature remains a major issue and a source of confusion: i) the investigators lose time in 
converting alternative gene name into the official one,  ii) the nomenclature in a database must not 
be ambiguous by definition  iii) the entries of a database are usually the starting points for further 
analyses (i.e. the intersection between two or more sources of information are partially captured 
only because the gene names are different) , iv) life sciences are interdisciplinary fields whose actors 
are not only biologists but also computer scientists, bioinformaticians and statisticians whose 
knowledge of the alternative gene names could be limited v) the search in PubMed can lead to 
incomplete results because the genes are annotated with different names. For all these reasons, in 
ATtRACT, we renamed the gene names according to the UniProt standard. 
Even though with ATtRACT, many databases have been integrated, more work needs to be done to 
better characterize the RBPs and their binding sites and more data needs to be integrated. For 
example, a huge source of information, neglected in ATtRACT and in all the other databases, is the 
recently published POSTAR database (Hu et al. 2016). POSTAR collects in a unique resource a large 
amount of CLIP-seq experiments (including HITS-CLIP, PAR-CLIP and iCLIP). We are planning to 
integrate these large amounts of data in the next release of ATtRACT 2.0. Additionally, ATtRACT, 
thanks to the presence of experimentally validated data, could be a precious resource for 
developing new and more accurate machine learning methods to predict the RBP binding sites. 
Recently, new machine learning methods have been developed to predict the sequence specificities 
of RNA-binding proteins. Among them DeepBind (Alipanahi et al. 2015) is considered one of the 
best. DeepBind employs a convolutional neural network and predicts RNA binding sequences of 207 
distinct RBPs. DeepBind was trained only with data available in CISBP-RNA, neglecting the 
information available in other databases, RNA secondary structure and the physicochemical 
properties of the amino acids in the RBD. To tackle all the aforementioned shortcomings, we plan 
to take advantage of the large amount of data available in ATtRACT and implement a “deep 
learning” method capable of predict RBP-RNA interactions better than the other state-of-the-art 
methods. 
The -omics data 
Cardiovascular diseases, including diseases of the heart and the blood vessels such as myocardial 
infarction, cardiac arrhythmias, and stroke, are the world's top cause of death and cause one-third 
death globally. Genome-wide and proteomics profile are nowadays necessary to fully understand 
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the molecular mechanisms that regulate the response to myocardial infarction in a global manner. 
The exploration of these mechanisms has considerable limitations in humans. In this regard, animal 
models of myocardial infarction play a critical role in biomedical research. However, the 
evolutionary gap between humans and small animals like rats or mice is a strong disadvantage for 
translational research. In this respect, the pig model for myocardial infarction gained massively in 
importance during the last years mainly because of many anatomical and physiological similarities 
with the human heart (Swindle et al. 2012). To our knowledge, this is the first study that successfully 
isolated CMs, FBs, ECs, and MFs from the pig infarcted area and that used transcriptomics and 
proteomics analyses on these cells in order to unveil the molecular mechanisms that regulate the 
response to infarction.  
Alternative splicing after MI 
AS is one of the main mechanism responsible for giving rise to the final set of transcripts present in 
a cell. Even though our knowledge of the molecular mechanisms that underlie post-infarction heart 
remodelling has increased over years, it remains still incomplete and mainly relates to gene 
expression data and does not consider the effect of AS changes after the myocardial infarction. A 
query in PubMed database with the words: “alternative splicing” and “myocardial infarction” 
produces only 41 manuscripts, meaning that very little is known about alternative splicing and its 
relationship with heart diseases. The current research regarding the role of AS in the context of 
heart failure is limited to the study of individual gene isoforms (Kong et al. 2010; Qiu et al. 2008; 
Woolard et al. 2009; Felkin et al. 2011). In this context, RNA-Seq analysis has greatly facilitated the 
study of alternative splicing, but the algorithms to detect the isoform switch remain a challenge for 
the computational biologists. The lack of guidelines and common practice in combination with the 
proliferation of several algorithms for the detection of AS events make it more difficult to establish 
an effective solution. We employed a pipeline that allowed us to detect, on a global scale, pairs of 
isoform switching transcripts after MI in 4 cell types at 3 different time points. We identified 210 
distinct genes undergoing AS in all the conditions, 41 of them were also detected at the protein 
level. It is important to notice that proteins must be expressed in a sufficient quantity to be 
identified. Hence the undetectability, at the protein level, of an alternatively spliced transcript does 
not mean that it is not translated.  
The main challenge concerned the interpretation of the impact and functions of alternatively spliced 
genes. An ORA of AS genes did not provide meaningful information suggesting that AS genes 
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regulate different processes but do not participate in a common process. The interpretation of the 
results remains a big issue. In this case, we considered that a literature mining of the most 
interesting and well annotated genes was the best approach even though time-consuming.  
Alternative splicing in Cardiomyocytes 
We detected 53 AS genes, 28 of them detected in CMs at day3v0, 35 at day7v0 and 17 at day7v3. 
Of these genes, 20 were in common between day3v0 and day7v0 suggesting that the same genes 
continued to be alternatively spliced also on day 7 (Fig 28A). The enriched BPs in any time contrast 
‘positive regulation of interleukin-2 biosynthetic process’, ’positive regulation of B cell 
differentiation’ and ‘B cell activation’ suggest that AS in CMs may play a role in the activation of the 
immune response.  
A literature analysis revealed that, in CMs, FHOD3, UXT and LRPPRC genes were the ones for which 
at least one article regarding their AS has been published. The FHOD3 gene was alternatively spliced 
in time contrast 7v3. The FHOD3 gene is mainly involved in the assembly and maintenance of cardiac 
myofibrils. Structurally, the gene is a member of the formin subfamily and contains multiple 
domains including the formin homology 2 domain (FH2). Iskratsch and collegues (Iskratsch et al. 
2010; Iskratsch et al. 2013) identified in CMs a novel striated muscle–specific micro-exon in FHOD3 
gene, which inserts as exon 26 in humans and as exon 25 in mice. This alternative exon is highly 
conserved between Zebrafish and Human. To assess whether the micro-exon is conserved also in 
pig, we performed a multiple sequence alignment of the nucleotide (Fig 64A) and amino acid 
sequences (Fig 64B). 
 
Figure 64: Multiple sequence alignment of conserved sequences of alternative spliced micro-exon in four species 
(Human, Pig, Rat and, Zebrafish). Identical and similar amino acids are indicated with stars and dots, respectively. The 
colours of the amino acid alignment (Fig 64B) represent the residues according to their physicochemical properties (Red 
: Small (small+ hydrophobic (incl.aromatic -Y)), Blue : Acidic, Magenta: Basic - H, Green : Hydroxyl + sulfhydryl + amine 
+ G, Grey: Unusual amino/imino acids etc) A) Multiple sequence alignment of nucleotide sequences. B) Multiple 
sequence alignment of translated region. 
The alignment showed a very high similarity in both nucleotide and amino acid sequences. The 
micro-exon encodes for eight additional amino acids at the C-terminal end of the FH2 domain. 
According to Iskratsch and collegues, this insertion introduces a phosphorylation site in the FH2 
domain which, if phosphorylated, alters its interaction with sequestosome 1 (SQSTM1). Thus, this 
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new isoform appears to be required for the myofibril maintenance. The authors also investigated 
the role of FHOD3 in cardiomyopathy, including myocardial ischemia, and detected a 
downregulation of the isoform containing the exon with a concomitant up-regulation of the exon–
lacking isoform. We observed an analogous behaviour in our data (Fig 65). Notice that we did not 
detect the isoform switch at time contrast 3v0 because our pipeline did not consider the expression 
of the isoform lacking the exon relevant, since it did not exceed the threshold of 1 TPM. 
 
Figure 65:  The expression profile of the FHOD3 gene is shown. The x-axis represents the time points, the y-axis 
represents the expression in terms of TPMs. A downregulation of isoforms containing the exon (blue line) with a 
concomitant up-regulation of the exon–lacking isoforms (orange line) can be observed. 
It has been proposed by Larochelle 2016; X. Yang et al. 2016 that alternative splicing can affect the 
way in which the proteins interact each other.  Alternatively spliced isoforms tend to behave like 
distinct proteins rather than minor variants. In this context, two alternatively spliced genes, UXT and 
LRPPRC, the last one detected also at proteins level, interact with each other. According to Moss et 
al. 2007, at higher expression levels, UXT interacts with LRPPRC leading to a progressive aggregation 
of mitochondria and cell death. AS of one of the genes can potentially disrupt this interaction and 
may lead to a pro-survival phenotype in CMs.  
Alternative splicing in Fibroblasts 
We detected 53 AS genes in FBs, 27 of them were detected at day3v0, 32 at day7v0 and 24 at 
day7v3. The enriched BPs did not provide any meaningful information about the role of alternative 
splicing in FBs. A literature mining did not show any relevant paper associated to the AS genes. An 
analysis of the BPs revealed that the HSD17B12 and ADAMTS12 genes are involved in the 
extracellular matrix organisation and cell-matrix adhesion respectively. ADAM8 is involved in 
extracellular matrix degradation (Choi et al. 2001). The role of AS in FBs requires further 
investigations. 
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Alternative splicing in Endothelial Cells 
We detected 86 AS genes in ECs, 41 of them were detected at day3v0, 46 at day7v0 and 43 at 
day7v3. The enrichment analysis of the ECs at time contrast 7v0 showed that 5 genes (CARMIL2, 
PDZD11, NPHP1, NCAM1, SGCA) were localised in cell-cell junction suggesting that these genes may 
play a role in maintaining the integrity of the endothelium and in leukocyte extravasation. 
A literature analysis revealed that, in ECs, MST1R, FST and SLBP genes were the ones for which there 
was information available about their alternative splicing. MST1R (also known as RON) gene is a 
tyrosine kinase receptor for the Macrophage-stimulating protein. It is involved in cell growth and 
protection from apoptosis, cell dissociation, motility, and matrix invasion.  ΔRON is an active isoform 
generated through the skipping of exon 11. This skipping provokes a change in the protein structure, 
as a consequence of which the ΔRon is always active also in the absence of its ligand, permitting to 
increase the cell motility (Collesi et al. 1996; Ghigna et al. 2005).  
One of the main roles of Follistatin (FST) is the inhibition of the myostatin activity. Myostatin is a 
transforming growth factor-β family member that negatively regulates skeletal muscle growth. 
Follistatin (FST) is alternatively spliced at time contrast 7v3 (Fig 66). The FST gene generates two 
isoforms, a long and a short one. The short isoform is much more efficient in the inhibition of the 
myostatin pathway compared to the long one (Hashimoto et al. 1997; Lee & McPherron 2001).  
 
Figure 66: The expression profile of the FST gene isoforms. The x-axis represents the days, the y-axis represents the 
expression in terms of TPMs. The isoform switch occurred at the time contrast 7v3. The short isoform (orange line) 
increased its expression at day 7 suggesting a potential role in promoting muscle growth 
This suggests that the short isoform of FST gene may play a role in promoting muscle growth by 
inhibiting the myostatin pathway. Additionally, it has been shown that adeno-associated virus-
mediated delivery of FST allows an increased muscle size and strength with reduced fibrosis in a 
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muscular dystrophy mouse model (Rodino-Klapac et al. 2009). This suggests a possible gene therapy 
treatment for MI. Interestingly, the Activin Type II receptor (ACVR2B) gene is alternatively spliced in 
FBs at the same time contrast.  It has been shown that ACVR2B competes with FST for the binding 
of Myostatin (Donaldson et al. 1999) suggesting an additional way to regulate the myostatin 
pathway through AS . 
The RNA-binding protein SLBP regulates the expression of all histone genes. SLBP is essential for 
histone mRNA 3′ end formation and is involved in the translation of histone mRNA. It also plays a 
role in the control of histone mRNA stability (Rattray & Muller 2012; Marzluff et al. 2008). The 
human SLBP gene generates, under replication stress conditions, two alternatively spliced variants 
lacking exon 3 and exon 2, respectively. According to Rattray et al. 2013, the isoform lacking exon 2 
is localised in the nucleus and the cytoplasm, making the SLBP gene partially unable to participate 
in histone mRNA regulation, whereas the isoform lacking exon 3 is localised in the nucleus. The same 
authors suggest that exon 3 is important for the binding of proteins involved in translation initiation, 
suggesting that alternative splicing of the SLBP gene is a way to control the histone gene expression. 
To assess whether these findings were valid also in pig, we performed a sequence alignment of the 
coding sequences of exon 2 and exon 3 between the pig gene and the human ortholog (Fig 67). 
 
Figure 67: Alignment of the coding region of Exon 2 and Exon 3 of the SLBP gene. Identical and similar amino acids are 
indicated with stars and dots, respectively. The colours represent the residues according to their physicochemical 
properties (Red : Small (small+ hydrophobic (incl.aromatic -Y)), Blue : Acidic, Magenta: Basic - H, Green : Hydroxyl + 
sulfhydryl + amine + G, Grey: Unusual amino/imino acids etc).  
The alignment showed a high similarity for exon 3, but a poor similarity for exon 2, suggesting that 
the findings might not be valid also in pig. 
Alternative splicing in Macrophages 
We detected 79 AS genes in MFs, 37 of them were detected at day3v0, 48 at day7v0 and 34 at 
day7v3. The standard ORA did not show any enriched GO term in any of the three domains of gene 
ontology. 
A literature analysis revealed that in MFs, AGER, and MUC1 were the main genes for which at least 
an article regarding AS had been published. The Receptor for Advanced Glycation End-products 
AGER (also known as RAGE) is a transmembrane protein expressed in the heart in CMs, ECs, FBs, 
and MFs (Ramasamy & Schmidt 2012). Lu et al. 2010 showed that RAGE and its ligands were 
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upregulated in the heart during ischemia/reperfusion and that oxidative stress was enhanced, 
Tsoporis et al. 2012 showed that S100B, via AGER ligation, favours FBs proliferation contributing to 
scar formation in infarcted myocardium, additionally antagonizing AGER allowed to reduce the 
infarcted area and to improve cardiac function. The AGER mRNA was alternatively spliced in time 
contrast 7v0 and 7v3. Alternative splicing of AGER mRNA in the pig alters the immunoglobulin-like 
domain that is necessary for the binding of S100B ligand (Leclerc et al. 2007). These isoforms may 
therefore serve as a binding regulator for the S100B ligand (Hudson et al. 2008).  
MUC1 mRNA was alternatively spliced in time contrast 7v0. MUC1 is a transmembrane protein 
whose main feature is the variable number of tandem repeats (VNTR) region forming the 
extracellular domain. The VNTR region can extend 300–500 nm above the cell surface playing a 
fundamental role in cell-cell and cell-matrix interactions (Fukuda 2002; Hilkens et al. 1992). 
Alternative splicing may regulate the extension of the VNTR region. In the pig, the VNTR is encoded 
by exon 1, we observed an expression of the long VNTR isoform mainly in day 0 and the short VNTR 
isoform in day 7. It has been suggested by Zhang et al. 2013 and Carson 2008 that the short isoform 
preserves important signalling functions or interfere with the long isoform by competing for ligand 
binding. 
Analyses of the domains 
Changing the sequence content of a gene product is one of the main characteristics of AS. In this 
respect, AS provides a new layer of complexity since it affects the protein structure and function. AS 
tends to alter the protein structure by inserting, deleting, and altering a proteins’ domain. The most 
interesting effects of AS on the proteins’ domain were found in the APOD and TNFRSF17 genes. AS 
of the APOD gene in CM at day 3v0 potentially changed the domain from a triabin domain to a 
lipocalin-like domain. For TNFRSF17, the BCMA, TALL-1 binding domain is inserted in CM at day 3v0 
and deleted in MFs at the same time contrast. Recent studies suggested that APOD gene is highly 
upregulated during heart failure (Wei et al. 2008). Additionally, it has been shown that APOD has 
cardioprotective effects on CMs in vitro in mouse models of MI with ischemia/reperfusion (I/R) 
injury (Tsukamoto et al. 2013). The same authors performed an adenovirus-mediated 
administration of APOD gene and detected a significant decrease in the infarct size suggesting a 
potential gene therapy approach. The triabin domain structurally looks similar to the lipocalin 
domain, they differ only in the direction of β-strands and in the general conformation of the β-
barrel. Triabin interacts with thrombin, the principal promoter of blood clotting and inhibits 
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vasoconstriction, platelet aggregation and coagulation (Fuentes-Prior et al. 1997; Hernández-Vargas 
et al. 2016). The APOD containing the lipocalin domain can bind to a number of ligands which may 
be protective including, progesterone, and arachidonic acid but with low affinity (Rassart et al. 
2000). Tsukamoto et al. 2013 suggested, in contrast, that APOD might be cardioprotective because 
it is an antioxidant. 
TNFRSF17 is a member of the TNF-receptor superfamily and in combination with TNF-related 
cytokines promotes cell death or cell proliferation and differentiation (Smith et al. 1994). 
Overexpression of the TNFRSF17, like in other members of the family, activates the mitogen-
activated protein kinase (MAPK) pathway and NF-κB, but, unlike the other members of the family, 
TNFRSF17 lacks of the “death domain”, suggesting that TNFRSF17 is involved in cell survival and 
proliferation (Hatzoglou et al. 2000). Hence, the insertion of the BCMA, TALL-1 binding domain in 
TNFRSF17 gene indicates that AS could play a role in the signals involved in CMs survival. However, 
the effect of the deletion of the same domain at the same time contrast in MFs remains unclear. 
Regulation of alternative splicing 
The lack of standard computational methods in combination with the complex regulatory layer 
generated by the RBPs-RNA interaction makes it difficult to assess the biological relevance of our in-
silico analysis, for this reason further experiments are needed. Here we developed a pipeline which 
makes use of MEME to find motifs overrepresented in the alternatively spliced exons and Tomtom 
to assess whether these motifs look like any of the ones available in ATtRACT. The main drawback 
of the pipeline is that it finds master regulators, meaning a set of RBPs regulating the majority 
alternatively spliced exons. This happens because the zoops model implemented in MEME assumes 
that each sequence may contain at most one occurrence of each motif. Therefore, to be 
overrepresented, a motif must be present in most of the sequences. Hence, it is not surprising that 
the overrepresented splicing factors hnRNPU and hnRNPD are the ones capable of binding RNA also 
non-specifically. This may be due to the fact that both splicing factors carry a RGG box region. The 
RGG box region confers the splicing factor the ability to bind to poly(A), poly(U), poly(G) and poly(C) 
with an intermediate affinity (Fackelmayer et al. 1994; Kiledjian & Dreyfuss 1992). However, the role 
of hnRNPU in the regulation of alternative splicing remains an open question. The group of 
Rappsilber et al. 2002 identified the hnRNPU as a core component of the spliceosome, the group of 
Zhou et al. 2002, on the contrary, did not find the protein. More recently has been suggested by 
Xiao et al. 2012 that hnRNPU is a global regulator of alternative splicing because regulates U2 snRNP 
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maturation. Additionally, Ye et al. 2015 showed that hnRNPU is necessary for normal pre-mRNA 
splicing and postnatal heart development and function. These findings may be in agreement with 
previous results showing that developmental mechanisms are reactivated following injury 
(Bergmann et al. 2015; Senyo et al. 2013). Additional experiments are necessary to validate our in-
silico analyses and the role of hnRNPD. Moreover, the computational methods for detecting the 
regulatory motifs need to be improved to gain a complete understanding of the alternative splicing 
regulatory mechanisms. 
Network-based enrichment analysis with MAGNETO: performance 
evaluation 
ORA is a common approach to assess whether there is a statistically significant overlap between a 
gene/protein set of interest and a database of known gene/protein sets representing cellular 
processes or pathways. Since proteins rarely act in isolation, the main limitation of the ORA method 
is that the molecular interaction network in a gene/protein set of interest is not considered. To solve 
this problem, here we developed a new network-based enrichment analysis method called 
MAGNETO.  
MAGNETO is a data-driven method whose main goal is to gain more insight into the molecular 
mechanisms of the phenotype under investigation by combining the advantages of topology-based 
methods and modules-based methods. MAGNETO initially splits the starting list of proteins/genes 
in modules. Each module represents a general biological process in accordance with the Reactome 
classification. Subsequently, MAGNETO exploits the information contained within the protein 
interaction network and in the expression of the proteins at the tissue level to expand the input list 
and detects additional functional associations not directly inferable with the standard ORA. 
Typically, MAGNETO yields a big list of novel functional associations, most of which are coherent 
with the phenotype and the literature references. Others represent potentially new BPs associated 
with the phenotype that never were investigated before. Therefore, MAGNETO could be of great 
use to formulate new hypotheses associated with a pool of proteins related to a phenotype. 
The main challenge, common to all the ORA methods, is to evaluate their performances. In 
MAGNETO we adopted the approach proposed by Tarca et al. 2012. The advantage of this method 
is that it eliminates any human bias in the interpretation of the results at the cost of having a dataset 
associated with a target pathway (for details please see the materials and methods section). A 
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disadvantage of the target pathway method is that it focuses only on a single pathway and neglects 
those BPs and pathways that may play a fundamental role in the phenotype.  
We evaluated MAGNETO on 21 real datasets. The evaluation was focused on the ability of 
MAGNETO to identify the target pathway as significant and with a rank as high as possible. 
MAGNETO outperformed the standard ORA when more than 50 genes/proteins were considered. It 
was also evident that MAGNETO allows to detect the target pathway with just a few proteins in the 
input, suggesting that it may be useful to investigate the biological impact of small lists of 
genes/proteins (i.e. less than 50). Additional benchmarks are needed to compare MAGNETO with 
other NBEA methods (i.e. Enrichnet, NET-GE, PINA) and gene set enrichment analysis methods 
(Subramanian et al. 2005). 
Large scale data analysis of the pig infarcted myocardium 
In a healthy myocardium, the most abundant cells are CMs, FBs, and ECs (Pinto et al. 2016). 
Subsequently to myocardial ischemia, these proportions are subject to variation and also MFs play 
a crucial role in the inflammation and healing of the myocardium (Frangogiannis 2014; Christia & 
Frangogiannis 2013). In this respect, ORA methods can provide an idea of the molecular mechanisms 
characterising the response to MI and to depict the role of each cell type.  
The current interest in the pig as a large animal model has raised the problem of the limited pig 
gene and protein annotations, efforts to provide a complete annotation of the pig genome and 
protein functions are still ongoing (Groenen 2016). Frequently, the annotations are transferred via 
sequence similarity. It is commonly accepted that proteins sharing more than 60% of sequence 
identity are also likely to share similar functions. Many of the annotated pig proteins have been 
inferred via sequence similarity methods and lack any experimental evidence. For this reason, we 
employed the human annotations to perform the ORA and converted the pig genes to one to one 
orthologue human genes. To compare MAGNETO and the standard ORA method, we employed the 
top 50 expressed genes in each cell type and time point. A term was considered enriched if the p-
value (Bonferroni corrected) was less than 0.001 
Analysis of overrepresented biological processes in all the cell types 
MAGNETO detected 178 unique BPs in total in all the cell types. In contrast, the standard ORA 
detected 48 unique BPs in total in all the cell types. It is important to note that MAGNETO increases 
the testing set at the risk that some BPs, overrepresented with the standard ORA, may not appear 
enriched in MAGNETO.  
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Cardiac repair after MI is an orchestrated event driven, mainly, by CMs, FBs, ECs and, MFs with 
sometimes overlapping roles (Talman & Ruskoaho 2016). Cardiac injury activates innate immune 
mechanisms initiating an inflammatory reaction. Therefore, it is not surprising that most of the 
enriched BPs following MI detected by MAGNETO and common in all the cell types and time points 
are related to the immune response and apoptosis (positive regulation of I-kappaB kinase/NF-
kappaB signalling, I-kappaB kinase/NF-kappaB signalling, positive regulation of NF-kappaB 
transcription factor activity, NIK/NF-kappaB signalling, NF-kappaB signalling, stimulatory C-type 
lectin receptor signalling pathway, T cell receptor signalling pathway, apoptosis). Many of these BPs 
have been experimentally validated (Cai et al. 2016, Lin & Knowlton 2014, Ghigo et al. 2014), 
suggesting that the results obtained with MAGNETO are biologically relevant. 
In CMs at day 0 most of the BPs, both in MAGNETO and in the standard ORA, are connected to 
muscle contraction and generation of energy. MAGNETO detected additional BPs associated with 
the inflammatory phase of MI (wound healing, platelet activation and platelet degranulation, Fc-
gamma receptor signalling pathway involved in phagocytosis) and with the generation of the scar 
(extracellular matrix organization, collagen catabolic process, positive regulation of cell 
proliferation, positive regulation of fibroblast proliferation). CMs at day 7 are characterised by the 
enrichment of BPs related to muscle contraction and cardiac remodelling detected by both 
MAGNETO and the standard ORA approach, suggesting that proteins involved in muscle contraction 
are reappearing in the infarcted area after the acute phase. Additionally, other enriched BPs 
revealed signals involved in cardiac regeneration and scar formation (heart development, blood 
vessel development, positive regulation of epithelial to mesenchymal transition, ERBB2 signalling 
pathway). Some of these BPs have been experimentally validated (Zhou & Pu 2011; Ozcelik et al. 
2002). 
in FBs, the BPs enriched, both with MAGNETO and the standard ORA approach, in all the time points 
reflect the inflammatory and proliferative phases of the cell type with BPs typical of cardiac 
regeneration, extracellular matrix degradation and synthesis (extracellular matrix organization, 
extracellular matrix disassembly, collagen catabolic process, collagen fibril organization). 
Additionally, MAGNETO detected BPs at day 3 and/or at day 7 involved in cell migration (positive 
regulation of fibroblast migration, cell migration, regulation of cell migration, positive regulation of 
cell migration), extracellular matrix organization (extracellular fibril organization, cell-matrix 
adhesion, substrate adhesion-dependent cell spreading and positive regulation of stress fiber 
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assembly) and recruitment of other cells employed as a source of fibroblasts (positive regulation of 
epithelial cell proliferation). This BP has been also experimentally validated (Hinz et al. 2007). 
Additionally, it has been shown that the epidermal growth factor induced heart fibrosis and 
proliferation of cardiac FBs (Lian et al. 2012) and the enriched BP “cellular response to epidermal 
growth factor stimulus” detected by MAGNETO seems to confirm this hypothesis. Finally, the BPs 
“transforming growth factor beta receptor signalling pathway” enriched at day 7 may regulate a 
wide range of cellular responses critical to cardiac repair. Also in FBs, we found several BPs 
experimentally validated, for a review of these BPs see Bujak & Frangogiannis 2007 . 
In ECs, the BP “angiogenesis” is overrepresented in all the time points with the standard ORA, in 
MAGNETO the same process is enriched only in day 0 and 7 but not in day 3. Additionally, MAGNETO 
enriches BPs related to ECs at day 0 (vascular endothelial growth factor receptor signalling pathway, 
ephrin receptor signalling pathway). These two pathways have been also experimentally validated 
(Gale & Yancopoulos 1999). The BPs enriched at day 3 and/or 7 confirm the role of ECs in immune 
response and regeneration (cell-cell adhesion, leukocyte migration, wound healing, blood vessel 
development transforming growth factor beta receptor signalling pathway, SMAD protein signal 
transduction, regulation of tumor necrosis factor-mediated signalling pathway, MhD88-dependent 
toll-like receptor signalling pathway, platelet activation, heart development, extracellular matrix 
organization, collagen catabolic process). Many of these BPs have been experimentally validated 
(Muller 2003, Sumpio et al. 2002, Saini et al. 2005, Euler 2015, Y. Yang et al. 2016, Michiels 2003, 
Guarda et al. 1993) 
Most of the BPs detected in MFs by MAGNETO are correlated with the immune response. 
Additionally, the BPs detected by MAGNETO are consistent with the inflammatory response and 
remodelling of the heart at day 3 (regulation of tumor necrosis factor-mediated signalling pathway, 
tumor necrosis factor-mediated signalling pathway, response to lipopolysaccharide, proteolysis 
involved in cellular protein catabolic process, insulin receptor signalling pathway, positive regulation 
of fibroblast proliferation, response to muscle stretch, cell-cell-adhesion, positive regulation of cell 
proliferation) and at day 7 (cellular response to fibroblast growth factor stimulus, cellular response 
to transforming growth factor beta stimulus, transforming growth factor beta receptor signalling 
pathway, leukocyte migration, collagen catabolic process, cell-cell-adhesion, response to muscle 
stretch). Some of these BPs have been experimentally validated (Chen & Frangogiannis 2016; Fujiu 
et al. 2014; Frangogiannis et al. 2002). 
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These few examples demonstrate that MAGNETO could be of great use to identify BPs and 
consequently also the proteins involved in a complex phenotype like the response to MI, for which 
the available knowledge is limited. Additionally, MAGNETO is of great use for the investigators to 
formulate new hypotheses, that need, eventually, to be tested in the laboratory.  
MAGNETO employs a data-driven approach, meaning that as the annotations of GO, Reactome and 
HPA improve, also the assignments of proteins to the modules and the detection of BPs will improve. 
Moreover, in this study we only showed the gene ontology domain related to BPs, but, in MAGNETO, 
other databases are integrated to give additional layers of knowledge and to better evaluate the 
protein list of interest in the context of pathways, diseases, viruses, toxins, and drugs. 
Finally, we believe that there is space for an improvement of MAGNETO’s algorithm. For example, 
instead of using the shortest path to connect two seed nodes, a more effective way could be the 
employment of the diffusion state distance (DSD) metric that is able to quantify topological 
similarity in a PIN in a more fine-grained way (Cao et al. 2014).  
In summary, MAGNETO represents a way of generating new knowledge from the available data, at 
no cost, allowing to propose new hypotheses and unveil new biological processes associated with a 
given phenotype. 
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Conclusions 
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1. ATtRACT collects in a unique resource all the experimentally validated RNA binding proteins 
and associated motifs that were previously spread across several databases. Compared to 
existing databases, ATtRACT adds 192 motifs not available in any other database by 
retrieving the information buried in the Protein Data Bank.  Currently, ATtRACT is the largest 
and most updated collection of experimentally validated RNA binding proteins and 
associated binding sites. 
 
2. In comparison with the heart of small animals, the pig heart shares many anatomical and 
physiological similarities with the human heart.  However, the use of pig as animal model 
has raised the problem of its functional annotation. The use of another species annotations 
through the identification of the gene orthologs helps to interpret the results when the 
species of interest is poorly annotated. 
 
3. Two hundred and ten genes were detected as alternatively spliced after myocardial 
infarction in cardiomyocytes, fibroblasts, endothelial cells, and macrophages. Forty-one 
were also detected at the protein level. These results indicate that either the technology 
sensitivity limits the number of alternative splicing events that can be detected in the 
infarcted heart or that very few AS events take place in response to a MI. 
 
4. A functional enrichment analysis of the alternatively spliced genes following myocardial 
infarction retrieved only few enriched terms supported by only few genes, suggesting that 
the identified genes did not participate in a common biological process. A literature analysis 
of these genes suggested that the alternative Apolipoprotein D and Follistatin isoforms were 
the ones that may have the strongest biological impact after myocardial infarction.  
 
5. The functional enrichment analysis is greatly improved when the protein interaction 
network is taken into account. In this respect, the benchmarks showed that MAGNETO 
outperforms the standard enrichment analysis from 50 proteins onwards. MAGNETO 
improves the ranks and the p-values of target pathways. Therefore, MAGNETO represents a 
precious resource to gain more biological knowledge also when a list of just a few 
genes/proteins is available.  
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6. Applied to the top 50 genes orthologs one to one to human expressed in the pig infarcted 
myocardium, MAGNETO provided more overrepresented terms. MAGNETO detected 178 
unique biological processes in total in all the cell types. In contrast, the standard enrichment 
analysis detected 48 unique biological processes in all the cell types. 
 
7. The biological processes detected in the pig infarcted myocardium with MAGNETO but not 
with the standard enrichment analysis method showed that all the cell types analysed, in 
response to MI, activate the innate immune mechanisms initiating an inflammatory reaction 
and at the same time deliver signals to promote cardiac remodelling and fibroblast 
proliferation.  
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1. ATtRACT recopila en un único repositorio todas las proteínas de unión a ARN y sus motivos 
asociados que estaban esparcidos por diversas bases de datos. Comparado con las demás 
bases de datos, ATtRACT añade 192 motivos más obtenidos mediante un algoritmo diseñado 
para extraer los motivos de los datos cristalográficos presentes en “Protein Data Bank”. 
Actualmente, ATtRACT es la colección más amplia y actualizada de proteínas de unión a ARN 
y sus motivos de interacción validados experimentalmente. 
 
2. En comparación con el corazón de animales pequeños, el corazón del cerdo comparte 
muchas similitudes anatómicas y fisiológicas con el corazón humano. Sin embargo, el uso del 
cerdo como animal modelo trae consigo el inconveniente de la deficiente anotación 
funcional de sus genes. El uso de las anotaciones de otras especies mediante la identificación 
de los genes ortólogos ayuda en la interpretación de los resultados cuando la especie de 
interés está poco anotada. 
 
3. Se han detectado en total doscientos diez genes con eventos de splicing alternativo después 
del infarto de miocardio en cardiomiocitos, fibroblastos, células endoteliales y macrófagos. 
Cuarenta y uno de esos eventos también se han detectado a nivel de proteína. Estos 
resultados indican que, o bien la sensibilidad de detección de la tecnología no es óptima, o 
bien el splicing alternativo no es un mecanismo relevante en la generación de cambios en 
respuesta al infarto de miocardio. 
 
4. El análisis de enriquecimiento funcional de estos eventos de splicing alternativo en respuesta 
al infarto de miocardio muestra pocos términos enriquecidos, y estos están a su vez 
soportados por muy pocos genes, sugiriendo que no hay ningún proceso biológico cuya 
regulación se base en el splicing alternativo como mecanismo principal. Un análisis basado 
en al literatura nos muestra que las isoformas alternativas de Apolipoproteina D y Folistatina 
son las que más impacto biológico podrían tener en el infarto de miocardio. 
 
5. El análisis de enriquecimiento funcional mejora drásticamente cuando se incorporan las 
redes de interacción proteína-proteína. A este respecto, los análisis de rendimiento 
muestran que MAGNETO supera a los métodos estándar de enriquecimiento funcional a 
partir de un número de 50 proteínas en adelante. MAGNETO mejora la clasificación y p-
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valores de las vías diana de este análisis. Por consiguiente, MAGNETO es una herramienta 
valiosa para mejorar el conocimiento biológico de un estado fenotípico dado cuando el 
número de genes disponible para su interpretación es reducido. 
 
6. Cuando usamos los ortólogos de humano de los 50 genes más expresados en el corazón de 
cerdo infartado, MAGNETO obtiene más términos sobrerrepresentados. MAGNETO detecta 
178 procesos biológicos en total entre todos los tipos celulares estudiados. Sin embargo, el 
análisis de enriquecimiento funcional estándar sólo detectó 48 procesos biológicos. 
 
7. Los procesos biológicos detectados con MAGNETO, y no con los métodos estándar, muestran 
que en todos los tipos celulares analizados, en respuesta al infarto de miocardio, se disparan 
los mecanismos para activar la respuesta inmune innata iniciando una reacción inflamatoria 
y al mismo tiempo liberan señales que promueven el remodelado cardíaco y la proliferación 
de fibroblastos. 
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Sonntag,M., Geerlof,A., Gabel,F., Gebauer,F. and Sattler,M. (2014) 
Structural basis for the assembly of the Sxl-Unr translation regulatory 
complex. Nature, 515, 287–290. (see figure 2f ) 
GUGA 
||||||| 
UUUUUUU 
distance: 4 
>FBGN0264270 
UGUUUUUUUU 
|||||||| 
UUUUUUUU 
distance: 1 
>FBGN0264270 see Hennig,J., Militti,C., Popowicz,G.M., Wang,I., 
Sonntag,M., Geerlof,A., Gabel,F., Gebauer,F. and Sattler,M. (2014) 
Structural basis for the assembly of the Sxl-Unr translation regulatory 
complex. Nature, 515, 287–290. 
GCACG 
||||||| 
UUUUUUU 
distance: 5 
>FBGN0264270 
UUUUUUUGAGCA 
||||||| 
UUUUUUU 
distance: 0 
>ENSG00000063244 
UUUUUUU 
||||||| 
UUUUUUC 
distance: 1 
>ENSG00000063244 
UUUUU 
||||||| 
UUUUUCC 
distance: 0 
>ENSG00000234414 
 ACAAGAC 
||||| 
CACAA 
distance: 0 
>ENSG00000131914 
AGGAGAU 
||||||| 
AGGAGAA 
distance: 1 
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>ENSG00000138385 
     UUUU 
||||||||| 
UGCUGUUUU 
distance: 0 
>ENSG00000138385 
    AUUU 
||||||||| 
UGCUGUUUU 
distance: 1 
>ENSG00000138385 
UGCUG 
||||||||| 
UGCUGUUUU 
distance: 0 
>WBGENE00001595 
  CUAAC 
|||||||||||| 
AUCUACUCAUAU 
distance: 2 
>WBGENE00001595 
  CUACUCAUAU 
|||||||||||| 
AUCUACUCAUAU 
distance: 0 
>ENSG00000078328 
UGCAUGU 
|||||| 
UGCAUG 
distance: 0 
>YOR359W see Aviv,T., Lin,Z., Ben-Ari,G., Smibert,C.A. and Sicheri,F. 
(2006) Sequence-specific recognition of RNA hairpins by the SAM domain of 
Vts1p. Nat. Struct. Mol. Biol., 13, 168–176. (figure 3a) 
UCUUUGA 
||||||| 
GCUGGUG 
distance: 4 
>YOR359W 
 CUGGCA 
||||||| 
GCUGGCC 
distance: 1 
>XB-GENE-6252591 see Lee,B.M., Xu,J., Clarkson,B.K., Martinez 
Yamout,M.A., Dyson,H.J., Case,D.A., Gottesfeld,J.M. and Wright,P.E. 
(2006) Induced Fit and ‘Lock and Key’ Recognition of 5 S {RNA} by 
Zinc Fingers of Transcription Factor {IIIA}. J. Mol. Biol., 357, 275–291. 
(figure 1b left) 
CCUGGUUAG 
||||||| 
GGGUGGG 
distance: 5 
>XB-GENE-6252591 see Lee,B.M., Xu,J., Clarkson,B.K., Martinez 
Yamout,M.A., Dyson,H.J., Case,D.A., Gottesfeld,J.M. and Wright,P.E. 
(2006) Induced Fit and ‘Lock and Key’ Recognition of 5 S {RNA} by 
Zinc Fingers of Transcription Factor {IIIA}. J. Mol. Biol., 357, 275–291. 
(figure 1b right) 
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CCAUAC 
||||||| 
GGGUGGG 
distance: 6 
>ENSG00000147274 
 UCAAA 
|||||| 
AUCAAA 
distance: 0 
>ENSG00000134644 
UGUAAUAUU 
|||||||| 
UGUAAAUA 
distance: 1 
>ENSG00000134644 see Gupta,Y.K., Nair,D.T., Wharton,R.P. and 
Aggarwal,A.K. (2008) Structures of Human Pumilio with Noncognate {RNAs} 
Reveal Molecular Mechanisms for Binding Promiscuity. Structure, 16, 549– 
557. 
UUUAAUGUU 
|||||||| 
UGUAAAUA 
distance: 4 
>ENSG00000134644 
UGUAUAUA 
|||||||| 
UGUAUAUA 
distance: 0 
>ENSG00000134644 
UGUAAAUA 
|||||||| 
UGUAAAUA 
distance: 0 
>ENSG00000134644 
UGUACAUA 
|||||||| 
UGUACAUA 
distance: 0 
>ENSG00000134644 
UGUACAUC 
|||||||| 
UGUACAUA 
distance: 1 
>ENSG00000134644 
UGUAGAUA 
|||||||| 
UGUAAAUA 
distance: 1 
>ENSG00000134644 
UGUCCAG 
|||||||| 
UGUACAUA 
distance: 2 
>ENSG00000134644 
UGUACAU 
|||||||| 
UGUACAUA 
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distance: 0 
>ENSG00000134644 
UGUAUAU 
|||||||| 
UGUAUAUA 
distance: 0 
>ENSG00000066044 
AUUUU 
||||| 
AUUUA 
distance: 1 
>ENSG00000066044 
UUUU 
||||| 
UUUUU 
distance: 0 
>ENSG00000066044 
AUUU 
||||| 
AUUUA 
distance: 0 
>ENSG00000112531 
ACUAAC 
|||||| 
ACUAAC 
distance: 0 
>YGL014W 
UGUAU 
|||||||| 
UGUAUAUA 
distance: 0 
>YGL014W 
UGUAUAUUA 
||||||||| 
UGUAUAUUA 
distance: 0 
>YGL014W 
UGUAUAUA 
|||||||| 
UGUAUAUA 
distance: 0 
>ENSG00000070756 
AAAAAAAA 
||||||| 
AAAAAAA 
distance: 0 
>ENSG00000070756 
AAAAAAA 
||||||| 
AAAAAAA 
distance: 0 
>ENSG00000077312 
AUUGCACC 
||||||| 
AUUGCAC 
distance: 0 
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>ENSG00000077312 
AUUGCAC 
||||||| 
AUUGCAC 
distance: 0 
>ENSG00000102081 no reference 
GCUGC 
||||||| 
GGACAGG 
distance: 4 
>YGL044C see Leeper,T.C., Qu,X., Lu,C., Moore,C. and Varani,G. (2010) 
Novel Protein–Protein Contacts Facilitate mRNA 3′-Processing Signal 
Recognition by Rna15 and Hrp1. J. Mol. Biol., 401, 334–349. 
AAUAAU 
|||||| 
UGUUGU 
distance: 4 
>YGL044C see Leeper,T.C., Qu,X., Lu,C., Moore,C. and Varani,G. (2010) 
Novel Protein–Protein Contacts Facilitate mRNA 3′-Processing Signal 
Recognition by Rna15 and Hrp1. J. Mol. Biol., 401, 334–349. 
UAUAUAUAA 
|||||| 
UGUUGU 
distance: 5 
>ENSG00000162374 
 UAUUUAUUUA 
|||||||||| 
UUAUUUAUUU 
distance: 1 
>ENSG00000162374 
AUUU 
||||||| 
UUUUUUU 
distance: 1 
>ENSG00000113742 
CUUUA 
|||||| 
UUUUUU 
distance: 2 
>ENSG00000055917 
UGUACAUC 
|||||||| 
UGUACAUA 
distance: 1 
>ENSG00000055917 
UGUAGAUA 
|||||||| 
UGUAGAUA 
distance: 0 
>ENSG00000055917 
UGUAAAUA 
|||||||| 
UGUAAAUA 
distance: 0 
>YLL013C 
UGUAUAUA 
175 
 
|||||||||| 
CAUGUAUAUA 
distance: 0 
>YLL013C 
UGUAAAUA 
|||||||||| 
CAUGUAAAUA 
distance: 0 
>YOL123W 
UAUAUAU 
||||||| 
UAUAUAA 
distance: 1 
>ENSG00000139910 
UCACC 
|||||| 
AUCACC 
distance: 0 
>ENSG00000139910 
 CAGUCAC 
|||||||| 
UCAGUCAC 
distance: 1 
>WBGENE00011279 see Kuwasako,K., Takahashi,M., Unzai,S., Tsuda,K., 
Yoshikawa,S., He,F., Kobayashi,N., Guntert,P., Shirouzu,M., Ito,T., et 
al. (2014) RBFOX and SUP-12 sandwich a G base to cooperatively regulate 
tissue-specific splicing. Nat. Struct. Mol. Biol., 21, 778–786. (results 
and figure 1a) 
 GUGUGC 
||||||| 
AGCAUGC 
distance: 3 
>WBGENE00011279 
UGCAUGG 
||||||| 
UGCAUGA 
distance: 1 
>ENSG00000104967 see Lewis,H.A., Musunuru,K., Jensen,K.B., Edo,C., 
Chen,H., Darnell,R.B. and Burley,S.K. (2000) Sequence-Specific {RNA} 
Binding by a Nova {KH} Domain: Implications for Paraneoplastic Disease 
and the Fragile X Syndrome. Cell, 100, 323–332. (figure 2 complex 1) 
CCUAGAUCACC 
|||||| 
AACACC 
distance: 5 
>ENSG00000104967 
GAUCACC 
|||||| 
AUCACC 
distance: 0 
>ENSG00000152518 
UUAUUUAUU 
||||||||| 
UUAUUUAUU 
distance: 0 
>ENSG00000120948 
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GUGAAUGA 
|||||| 
GAAUGA 
distance: 0 
>WBGENE00001402 
UGUGUUAUC 
||||||||| 
UGUGUUAUC 
distance: 0 
>WBGENE00001402 
UGUGCCUUA 
||||||||| 
UGUGCCAUA 
distance: 1 
>WBGENE00001402 
UGUAA 
||||||||| 
UGUAAAAUC 
distance: 0 
>WBGENE00001402 
UGUACCAUA 
||||||||| 
UGUACCAUA 
distance: 0 
>WBGENE00001402 see Qiu,C., Kershner,A., Wang,Y., Holley,C.P., 
Wilinski,D., Keles,S., Kimble,J., Wickens,M. and Hall,T.M.T. (2012) 
Divergence of Pumilio/fem-3 mRNA binding factor (PUF) protein specificity 
through variations in an RNA-binding pocket. J. Biol. Chem., 287, 6949– 
6957. (see paragraph An Upstream C Is Required for Tight Binding by FBF) 
CAUGUGC 
||||||||| 
UGUGUCAUC 
distance: 5 
>WBGENE00001402 see Wang,Y., Opperman,L., Wickens,M. and Hall,T.M.T. 
(2009) Structural basis for specific recognition of multiple mRNA targets 
by a PUF regulatory protein. Proc. Natl. Acad. Sci. U. S. A., 106, 20186– 
20191. (figure 2a) 
CUGUGC 
||||||||| 
UGUGCCAUA 
distance: 1 
>WBGENE00001402 see Wang,Y., Opperman,L., Wickens,M. and Hall,T.M.T. 
(2009) Structural basis for specific recognition of multiple mRNA targets 
by a PUF regulatory protein. Proc. Natl. Acad. Sci. U. S. A., 106, 20186– 
20191. (figure 2b) 
 AUAC 
||||||||| 
UGUAAAAUC 
distance: 3 
>WBGENE00001402 
UGUGUCAUU 
||||||||| 
UGUGUCAUU 
distance: 0 
>WBGENE00001402 
UGUGC 
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||||||||| 
UGUGCCAUA 
distance: 0 
>WBGENE00001402 
UGUACUAUA 
||||||||| 
UGUACUAUA 
distance: 0 
>ENSG00000048740 
UGUU 
||||| 
AUGUU 
distance: 0 
>ENSG00000168066 
AUACUAACAA 
||||||||||| 
UAUACUAACAA 
distance: 0 
>ENSMUSG00000003410 
AUUUAUUUU 
||||||| 
UUUUUUU 
distance: 1 
>ENSG00000136527 
AGAA 
||||| 
AAGAA 
distance: 0 
>ENSG00000136527 
AGAAC 
|||||| 
AAGAAC 
distance: 0 
>ENSG00000136450 
UGAAGGAC 
|||||||| 
AGAAGGAC 
distance: 1 
>WBGENE00006321 
 GUGUGC 
||||||| 
AGUGUGA 
distance: 1 
>WBGENE00006321 
GUGUG 
||||||| 
AGUGUGA 
distance: 0 
>YLR116W 
AUACUAAC 
||||||| 
UACUAAC 
distance: 0 
>YLR116W 
UACUAACA 
||||||| 
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UACUAAC 
distance: 0 
>YLR116W 
UACUAAC 
||||||| 
UACUAAC 
distance: 0 
 
